

# A 9-Valent HPV Vaccine against Infection and Intraepith

New England Journal of Medicine

372, 711-723

DOI: [10.1056/nejmoa1405044](https://doi.org/10.1056/nejmoa1405044)

Citation Report

#	ARTICLE	IF	CITATIONS
1	Global Genomic Diversity of Human Papillomavirus 6 Based on 724 Isolates and 190 Complete Genome Sequences. <i>Journal of Virology</i> , 2014, 88, 7307-7316.	1.5	33
2	High-risk human papillomavirus cervical infections among healthy women in Guadeloupe. <i>International Journal of Infectious Diseases</i> , 2015, 41, 13-16.	1.5	17
3	How can we achieve HPV control in Europe?. <i>Future Virology</i> , 2015, 10, 1125-1127.	0.9	1
4	Clinicopathologic Features Associated With Human Papillomavirus/p16 in Patients With Metastatic Squamous Cell Carcinoma of the Anal Canal. <i>Oncologist</i> , 2015, 20, 1247-1252.	1.9	28
5	HPV9: Combating HPV-associated cancers by strengthening serotype defenses. <i>Journal of the American Pharmacists Association: JAPhA</i> , 2015, 55, 670-672.	0.7	0
6	High-risk human papillomavirus genotypes distribution in a cohort of HIV-positive women living in Europe. <i>Aids</i> , 2015, 30, 1.	1.0	14
7	Tenofovir-Based Preexposure Prophylaxis for HIV Infection Among African Women. <i>Obstetrical and Gynecological Survey</i> , 2015, 70, 444-446.	0.2	8
8	Immunizing adolescents. <i>Current Opinion in Pediatrics</i> , 2015, 27, 405-417.	1.0	7
9	Targeted Therapy in Oropharyngeal Squamous Cell Carcinoma: The Implications of HPV for Therapy. <i>Rare Cancers and Therapy</i> , 2015, 3, 89-117.	0.2	13
10	Durable immunity to oncogenic human papillomaviruses elicited by adjuvanted recombinant Adeno-associated virus-like particle immunogen displaying L2 17â€³36 epitopes. <i>Vaccine</i> , 2015, 33, 5553-5563.	1.7	19
11	HPV9 Vaccine for the Prevention of Human Papillomavirusâ€“Related Cancers. <i>Nursing for Women's Health</i> , 2015, 19, 365-370.	0.3	2
12	Human papillomavirus prevalence in South African women and men according to age and human immunodeficiency virus status. <i>BMC Infectious Diseases</i> , 2015, 15, 459.	1.3	42
13	Are we missing an opportunity for cancer prevention? Human papillomavirus vaccination for survivors of pediatric and young adult cancers. <i>Cancer</i> , 2015, 121, 3395-3402.	2.0	10
14	Current status of human papillomavirus vaccination. <i>Current Opinion in Oncology</i> , 2015, 27, 399-404.	1.1	28
15	Gender-neutrality, herd effect and resilient immune response for sustainable impact of HPV vaccination. <i>Current Opinion in Obstetrics and Gynecology</i> , 2015, 27, 326-332.	0.9	9
16	An Open-Label, Randomized Study of a 9-Valent Human Papillomavirus Vaccine Given Concomitantly with Diphtheria, Tetanus, Pertussis and Poliomyelitis Vaccines to Healthy Adolescents 11â€“15 Years of Age. <i>Pediatric Infectious Disease Journal</i> , 2015, 34, 627-634.	1.1	31
17	<sc>HPV</sc> genotype distribution in older Danish women undergoing surgery due to cervical cancer. <i>Acta Obstetricia Et Gynecologica Scandinavica</i> , 2015, 94, 1262-1268.	1.3	10
18	The role of human papillomaviruses in carcinogenesis. <i>Ecancermedicalscience</i> , 2015, 9, 526.	0.6	123

#	ARTICLE	IF	CITATIONS
19	Evaluaci3n positiva de medicamentos: marzo/abril/mayo 2015. <i>Sanidad Militar</i> , 2015, 71, 186-195.	0.0	0
20	The Promise of Preventive Cancer Vaccines. <i>Vaccines</i> , 2015, 3, 467-489.	2.1	38
21	The Interaction between Human Immunodeficiency Virus and Human Papillomaviruses in Heterosexuals in Africa. <i>Journal of Clinical Medicine</i> , 2015, 4, 579-592.	1.0	58
22	Immunologic Control of <i>Mus musculus</i> Papillomavirus Type 1. <i>PLoS Pathogens</i> , 2015, 11, e1005243.	2.1	42
23	Knowledge on HPV Vaccine and Cervical Cancer Facilitates Vaccine Acceptability among School Teachers in Kitui County, Kenya. <i>PLoS ONE</i> , 2015, 10, e0135563.	1.1	48
24	Relationship between Humoral Immune Responses against HPV16, HPV18, HPV31 and HPV45 in 12-15 Year Old Girls Receiving Cervarix® or Gardasil® Vaccine. <i>PLoS ONE</i> , 2015, 10, e0140926.	1.1	17
25	Identifying and Overcoming Perceived Barriers of Providers towards HPV Vaccination: A Literature Review. <i>Journal of Vaccines</i> , 2015, 2015, 1-7.	0.6	10
26	Are the Two Human Papillomavirus Vaccines Really Similar? A Systematic Review of Available Evidence: Efficacy of the Two Vaccines against HPV. <i>Journal of Immunology Research</i> , 2015, 2015, 1-13.	0.9	18
27	Monitoring Effect of Human Papillomavirus Vaccines in US Population, Emerging Infections Program, 2008-2012. <i>Emerging Infectious Diseases</i> , 2015, 21, 1557-1561.	2.0	18
28	From the monovalent to the nine-valent HPV vaccine. <i>Clinical Microbiology and Infection</i> , 2015, 21, 827-833.	2.8	57
30	Who should be vaccinated against HPV?. <i>BMJ</i> , The, 2015, 350, h2244-h2244.	3.0	7
31	Systematic review of model-based cervical screening evaluations. <i>BMC Cancer</i> , 2015, 15, 334.	1.1	36
32	Seroepidemiology of Human Papillomavirus 16 (HPV16) L2 and Generation of L2-Specific Human Chimeric Monoclonal Antibodies. <i>Vaccine Journal</i> , 2015, 22, 806-816.	3.2	19
33	Efficacy of fewer than three doses of an HPV-16/18 AS04-adjuvanted vaccine: combined analysis of data from the Costa Rica Vaccine and PATRICIA trials. <i>Lancet Oncology</i> , The, 2015, 16, 775-786.	5.1	247
34	Towards cervical cancer eradication: joint force of HPV vaccination and HPV-based cervical cancer screening. <i>Clinical Microbiology and Infection</i> , 2015, 21, 806-807.	2.8	7
35	A Randomized, Double-Blind, Phase III Study of the Immunogenicity and Safety of a 9-Valent Human Papillomavirus L1 Virus-Like Particle Vaccine (V503) Versus Gardasil® in 9-15-Year-Old Girls. <i>Pediatric Infectious Disease Journal</i> , 2015, 34, 992-998.	1.1	89
36	A 9-Valent HPV Vaccine in Women. <i>New England Journal of Medicine</i> , 2015, 372, 2566-2569.	13.9	13
38	Rates and predictors of genital warts burden in the Czech population. <i>International Journal of Infectious Diseases</i> , 2015, 35, 29-33.	1.5	10

#	ARTICLE	IF	CITATIONS
39	HPV "Coverage". New England Journal of Medicine, 2015, 372, 775-776.	13.9	22
40	Immunogenicity and safety of an E. coli-produced bivalent human papillomavirus (type 16 and 18) vaccine: A randomized controlled phase 2 clinical trial. Vaccine, 2015, 33, 3940-3946.	1.7	21
42	How to best measure the effectiveness of male human papillomavirus vaccine programmes?. Clinical Microbiology and Infection, 2015, 21, 834-841.	2.8	15
43	Naturally Occurring Capsid Protein Variants of Human Papillomavirus Genotype 31 Represent a Single L1 Serotype. Journal of Virology, 2015, 89, 7748-7757.	1.5	12
44	Immunogenicity and Safety of a 9-Valent HPV Vaccine. Pediatrics, 2015, 136, e28-e39.	1.0	105
45	Inflammation and Cancer: What Can We Therapeutically Expect from Checkpoint Inhibitors?. Current Urology Reports, 2015, 16, 59.	1.0	15
46	Gardasil 9 joins the fight against cervix cancer. Expert Review of Vaccines, 2015, 14, 1047-1049.	2.0	42
47	Immunogenicity and safety of the 9-valent HPV vaccine in men. Vaccine, 2015, 33, 6892-6901.	1.7	104
48	Phase II studies to select the formulation of a multivalent HPV L1 virus-like particle (VLP) vaccine. Human Vaccines and Immunotherapeutics, 2015, 11, 1313-1322.	1.4	31
49	Human papillomavirus genotype attribution for HPVs 6, 11, 16, 18, 31, 33, 45, 52 and 58 in female anogenital lesions. European Journal of Cancer, 2015, 51, 1732-1741.	1.3	172
50	Immunogenicity and safety of the human papillomavirus vaccine in patients with autoimmune diseases: A systematic review. Vaccine, 2015, 33, 3444-3449.	1.7	20
51	Present status of human papillomavirus vaccine development and implementation. Lancet Oncology, The, 2015, 16, e206-e216.	5.1	165
52	Primary endpoints for future prophylactic human papillomavirus vaccine trials: towards infection and immunobridging. Lancet Oncology, The, 2015, 16, e226-e233.	5.1	66
54	Design of a large outcome trial for a multivalent human papillomavirus L1 virus-like particle vaccine. Contemporary Clinical Trials, 2015, 42, 18-25.	0.8	19
55	Safety and immunogenicity of a 9-valent HPV vaccine in females 12-26 years of age who previously received the quadrivalent HPV vaccine. Vaccine, 2015, 33, 6855-6864.	1.7	67
56	9-Valent HPV vaccine for cancers, pre-cancers and genital warts related to HPV. Expert Review of Vaccines, 2015, 14, 1405-1419.	2.0	38
57	Tuberculosis vaccine development: Shifting focus amid increasing development challenges. Human Vaccines and Immunotherapeutics, 2015, 11, 1910-1916.	1.4	5
58	An anal cancer screening program for MSM in Italy: Prevalence of multiple HPV types and vaccine-targeted infections. Journal of Clinical Virology, 2015, 72, 49-54.	1.6	14

#	ARTICLE	IF	CITATIONS
60	Extending the Human Papillomavirus Vaccination Programme to Include Males in High-Income Countries: A Systematic Review of the Cost-Effectiveness Studies. <i>Clinical Drug Investigation</i> , 2015, 35, 471-485.	1.1	28
61	HPV Vaccination: Current Global Status. <i>Current Obstetrics and Gynecology Reports</i> , 2015, 4, 220-233.	0.3	20
63	Coadministration of a 9-Valent Human Papillomavirus Vaccine With Meningococcal and Tdap Vaccines. <i>Pediatrics</i> , 2015, 136, e563-e572.	1.0	49
64	Reduced dose human papillomavirus vaccination: An update of the current state-of-the-art. <i>Vaccine</i> , 2015, 33, 5042-5050.	1.7	16
65	The Beginning of the End: Vaccine Prevention of HPV-Driven Cancers. <i>Journal of the National Cancer Institute</i> , 2015, 107, djv128-djv128.	3.0	7
66	Sexually Transmitted Infections. <i>Urologic Clinics of North America</i> , 2015, 42, 507-518.	0.8	29
67	Primary Care for Men Who Have Sex with Men. <i>New England Journal of Medicine</i> , 2015, 373, 854-862.	13.9	23
68	Human Papillomavirus and Its Role in Cervical Cancer Screening and Treatment. <i>Current Treatment Options in Infectious Diseases</i> , 2015, 7, 217-229.	0.8	0
69	HPV vaccination and pregnancy. <i>BMJ, The</i> , 2015, 351, h4705.	3.0	8
70	Impact of quadrivalent human papillomavirus vaccine in women at increased risk of genital warts burden: Population-based cross-sectional survey of Czech women aged 16 to 40 years. <i>Vaccine</i> , 2015, 33, 6264-6267.	1.7	15
71	Providers' beliefs about the effectiveness of the HPV vaccine in preventing cancer and their recommended age groups for vaccination: Findings from a provider survey, 2012. <i>Preventive Medicine</i> , 2015, 81, 405-411.	1.6	30
72	Human Papillomavirus Vaccine. <i>Advances in Protein Chemistry and Structural Biology</i> , 2015, 101, 231-322.	1.0	20
74	HPV prophylactic vaccines: lessons learned from 10 years experience. <i>Future Virology</i> , 2015, 10, 999-1009.	0.9	7
75	Human Papillomaviruses. , 2016, , 413-426.		0
76	Papillomavirus. , 2016, , 625-678.		0
77	Genotype Distribution of Human Papillomavirus among Women with Cervical Cytological Abnormalities or Invasive Squamous Cell Carcinoma in a High-Incidence Area of Esophageal Carcinoma in China. <i>BioMed Research International</i> , 2016, 2016, 1-6.	0.9	10
78	Population-Level Effects of Human Papillomavirus Vaccination Programs on Infections with Nonvaccine Genotypes. <i>Emerging Infectious Diseases</i> , 2016, 22, 1732-1740.	2.0	77
79	Ten years of anti-HPV vaccinations: what do we know?. <i>Przegląd Menopauzalny</i> , 2016, 3, 170-175.	0.6	7

#	ARTICLE	IF	CITATIONS
80	Spotlight on the 9-valent HPV vaccine. <i>Drug Design, Development and Therapy</i> , 2017, Volume11, 35-44.	2.0	24
81	Summary of emerging targets in anal cancer: the case for an immunotherapy based-approach. <i>Journal of Gastrointestinal Oncology</i> , 2016, 7, 721-726.	0.6	7
83	Prevalence characteristics of high-risk human papillomaviruses in women living in Shanghai with cervical precancerous lesions and cancer. <i>Oncotarget</i> , 2016, 7, 24656-24663.	0.8	22
84	Development of a Triple-Color Pseudovirion-Based Assay to Detect Neutralizing Antibodies against Human Papillomavirus. <i>Viruses</i> , 2016, 8, 107.	1.5	25
85	Human Papillomavirus Vaccines. , 2016, , 245-263.		14
86	Preventing Cervical Cancer in the United States: Barriers and Resolutions for HPV Vaccination. <i>Frontiers in Oncology</i> , 2016, 6, 19.	1.3	51
87	Long-Term Follow-up of HPV Infection Using Urine and Cervical Quantitative HPV DNA Testing. <i>International Journal of Molecular Sciences</i> , 2016, 17, 750.	1.8	15
88	Major clinical research advances in gynecologic cancer in 2015. <i>Journal of Gynecologic Oncology</i> , 2016, 27, e53.	1.0	20
89	La vacuna contra el Virus del Papiloma Humano: estado de la cuesti3n, principio de proporcionalidad y consentimiento informado. <i>Acta Bioethica</i> , 2016, 22, 251-261.	0.1	2
90	HPV Infection and Prevention of HPV Infection in Men Who Have Sex with Men (MSM). , 0, , .		1
91	Human papillomavirus epidemiology and vaccine recommendations. <i>Current Opinion in Pediatrics</i> , 2016, 28, 400-406.	1.0	7
92	Eurogin Roadmap 2015: How has HPV knowledge changed our practice: Vaccines. <i>International Journal of Cancer</i> , 2016, 139, 510-517.	2.3	19
93	Multiple human papillomavirus infections and type-competition in women from a clinic attendee population in China. <i>Journal of Medical Virology</i> , 2016, 88, 1989-1998.	2.5	3
94	Efficacy, safety, and immunogenicity of the human papillomavirus 16/18 AS04-adjuvanted vaccine in women older than 25 years: 7-year follow-up of the phase 3, double-blind, randomised controlled VIVIANE study. <i>Lancet Infectious Diseases</i> , The, 2016, 16, 1154-1168.	4.6	148
95	Cervical cancer control in Latin America: A call to action. <i>Cancer</i> , 2016, 122, 502-514.	2.0	32
96	Functional assessment and structural basis of antibody binding to human papillomavirus capsid. <i>Reviews in Medical Virology</i> , 2016, 26, 115-128.	3.9	11
97	Clinical characteristics and outcomes of oropharyngeal carcinoma related to high-risk non-human papillomavirus16 viral subtypes. <i>Head and Neck</i> , 2016, 38, 1330-1337.	0.9	33
98	The male ScreenING Study: prevalence of HPV-related genital and anal lesions in an urban cohort of HIV-positive men in Germany. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2016, 30, 995-1001.	1.3	34

#	ARTICLE	IF	CITATIONS
99	HPV vaccines: how many doses are needed for protection?. <i>Future Virology</i> , 2016, 11, 283-292.	0.9	0
100	Carcinogenic human papillomavirus infection. <i>Nature Reviews Disease Primers</i> , 2016, 2, 16086.	18.1	615
101	Two vs Three Doses of Human Papillomavirus Vaccine. <i>JAMA - Journal of the American Medical Association</i> , 2016, 316, 2370.	3.8	12
102	Immunogenicity of the 9-Valent HPV Vaccine Using 2-Dose Regimens in Girls and Boys vs a 3-Dose Regimen in Women. <i>JAMA - Journal of the American Medical Association</i> , 2016, 316, 2411.	3.8	147
103	Background and Current Treatment of Squamous Cell Carcinoma of the Anus. <i>Oncology and Therapy</i> , 2016, 4, 135-172.	1.0	18
104	Controlled Hybrid-Assembly of HPV16/18 L1 Bi VLPs in Vitro. <i>ACS Applied Materials &amp; Interfaces</i> , 2016, 8, 34244-34251.	4.0	7
105	Continuing reductions in HPV 16/18 in a population with high coverage of bivalent HPV vaccination in England: an ongoing cross-sectional study. <i>BMJ Open</i> , 2016, 6, e009915.	0.8	54
106	The DE and FG loops of the HPV major capsid protein contribute to the epitopes of vaccine-induced cross-neutralising antibodies. <i>Scientific Reports</i> , 2016, 6, 39730.	1.6	32
107	Vaccines against human papillomavirus infections: protection against cancer, genital warts or both?. <i>Clinical Microbiology and Infection</i> , 2016, 22, S125-S127.	2.8	23
108	Immune responses after two- versus three-doses of HPV vaccination up to 4½ years post vaccination: an observational study among Dutch routinely vaccinated girls (HPV2D). <i>Journal of Infectious Diseases</i> , 2017, 215, jiw588.	1.9	14
109	Effectiveness of HPV vaccination on prevalence of vaccine genotypes in young sexually active women in France. <i>Journal of Infectious Diseases</i> , 2017, 215, jiw639.	1.9	19
110	Population-level impact, herd immunity, and elimination after human papillomavirus vaccination: a systematic review and meta-analysis of predictions from transmission-dynamic models. <i>Lancet Public Health</i> , The, 2016, 1, e8-e17.	4.7	210
111	HPV vaccination intention among male clients of a large STI outpatient clinic in Amsterdam, the Netherlands. <i>Papillomavirus Research (Amsterdam, Netherlands)</i> , 2016, 2, 178-184.	4.5	10
112	CryoPen® , A gasless cryotherapy system adapted for low-resource settings. , 2016, , .		1
113	Development of World Health Organization (WHO) recommendations for appropriate clinical trial endpoints for next-generation Human Papillomavirus (HPV) vaccines. <i>Papillomavirus Research (Amsterdam, Netherlands)</i> , 2016, 2, 185-189.	4.5	11
114	Global Genomic Diversity of Human Papillomavirus 11 Based on 433 Isolates and 78 Complete Genome Sequences. <i>Journal of Virology</i> , 2016, 90, 5503-5513.	1.5	20
115	Gardasil-9: A global survey of projected efficacy. <i>Antiviral Research</i> , 2016, 130, 101-109.	1.9	111
116	Review of Statistical Innovations in Trials Supporting Vaccine Clinical Development. <i>Statistics in Biopharmaceutical Research</i> , 2016, 8, 128-142.	0.6	5

#	ARTICLE	IF	CITATIONS
117	Taking stock and looking ahead: Behavioural science lessons for implementing the nonavalent human papillomavirus vaccine. <i>European Journal of Cancer</i> , 2016, 62, 96-102.	1.3	3
118	Impact and Effectiveness of the Quadrivalent Human Papillomavirus Vaccine: A Systematic Review of 10 Years of Real-world Experience. <i>Clinical Infectious Diseases</i> , 2016, 63, 519-527.	2.9	360
119	Comparison of 2-Dose and 3-Dose 9-Valent Human Papillomavirus Vaccine Schedules in the United States: A Cost-effectiveness Analysis. <i>Journal of Infectious Diseases</i> , 2016, 214, 685-688.	1.9	37
120	HPV Update: Vaccination, Screening, and Associated Disease. <i>Journal of General Internal Medicine</i> , 2016, 31, 1360-1366.	1.3	22
121	Prophylactic HPV vaccination: past, present, and future. <i>Epidemiology and Infection</i> , 2016, 144, 449-468.	1.0	128
122	Parental acceptance and uptake of the HPV vaccine among African-Americans and Latinos in the United States: A literature review. <i>Social Science and Medicine</i> , 2016, 159, 116-126.	1.8	93
123	Younger age at initiation of the human papillomavirus (HPV) vaccination series is associated with higher rates of on-time completion. <i>Preventive Medicine</i> , 2016, 89, 327-333.	1.6	54
124	Genetic variability and phylogeny analysis of partial L1 gene of human papillomavirus variants in Buenos Aires, Argentina. <i>VirusDisease</i> , 2016, 27, 41-47.	1.0	8
126	Ten years of HPV vaccines: State of art and controversies. <i>Critical Reviews in Oncology/Hematology</i> , 2016, 102, 65-72.	2.0	52
127	American Society of Clinical Oncology Statement: Human Papillomavirus Vaccination for Cancer Prevention. <i>Journal of Clinical Oncology</i> , 2016, 34, 1803-1812.	0.8	83
128	National- and state-level impact and cost-effectiveness of nonavalent HPV vaccination in the United States. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2016, 113, 5107-5112.	3.3	46
129	Comparison of cytology, HPV DNA testing and HPV 16/18 genotyping alone or combined targeting to the more balanced methodology for cervical cancer screening. <i>Gynecologic Oncology</i> , 2016, 142, 120-127.	0.6	22
130	Expanding the benefits of HPV vaccination to boys and men. <i>Lancet, The</i> , 2016, 387, 1798-1799.	6.3	30
131	Characterization of serum antibodies from women immunized with Gardasil: A study of HPV-18 infection of primary human keratinocytes. <i>Vaccine</i> , 2016, 34, 3171-3177.	1.7	2
132	Is HPV vaccination in pregnancy safe?. <i>Human Vaccines and Immunotherapeutics</i> , 2016, 12, 1960-1964.	1.4	20
133	Broad Cross-Protection Is Induced in Preclinical Models by a Human Papillomavirus Vaccine Composed of L1/L2 Chimeric Virus-Like Particles. <i>Journal of Virology</i> , 2016, 90, 6314-6325.	1.5	29
134	Determining If Sex Bias Exists in Human Surgical Clinical Research. <i>JAMA Surgery</i> , 2016, 151, 1022.	2.2	96
135	Letter to the Editor; P. Van Damme et al. <i>Vaccine</i> 34 (2016) 757-761. <i>Vaccine</i> , 2016, 34, 4271.	1.7	0



#	ARTICLE	IF	CITATIONS
136	A Single Human Papillomavirus Vaccine Dose Improves B Cell Memory in Previously Infected Subjects. EBioMedicine, 2016, 10, 55-64.	2.7	53
137	Human Papillomavirus Infection and Vaccination in Males. European Urology Focus, 2016, 2, 355-362.	1.6	16
138	Human Papillomavirus Vaccination Requirements in US Schools: Recommendations for Moving Forward. American Journal of Public Health, 2016, 106, 1765-1770.	1.5	16
139	Improved antiviral activity of a polyamide against high-risk human papillomavirus via N-terminal guanidinium substitution. MedChemComm, 2016, 7, 2076-2082.	3.5	8
140	Congenital anomalies: Case definition and guidelines for data collection, analysis, and presentation of immunization safety data. Vaccine, 2016, 34, 6015-6026.	1.7	74
141	A paper-based immunoassay to determine HPV vaccination status at the point-of-care. Vaccine, 2016, 34, 5656-5663.	1.7	10
142	Health Care Maintenance for the Pediatric Patient With Inflammatory Bowel Disease. Pediatrics, 2016, 138, .	1.0	32
143	Human papillomavirus vaccination guideline update: American Cancer Society guideline endorsement. Ca-A Cancer Journal for Clinicians, 2016, 66, 375-385.	157.7	60
144	Human papillomavirus-related oropharyngeal cancer in the HIV-infected population. Oral Diseases, 2016, 22, 98-106.	1.5	27
145	Prevalence of human papillomavirus types in cervical cancerous and precancerous lesions of Ecuadorian women. Journal of Medical Virology, 2016, 88, 144-152.	2.5	19
146	Management of high-risk HPV-positive women for detection of cervical (pre)cancer. Expert Review of Molecular Diagnostics, 2016, 16, 961-974.	1.5	45
147	Cancer Prevention: HPV Vaccination. Seminars in Oncology Nursing, 2016, 32, 273-280.	0.7	17
148	New Vaccines on the Horizon. Current Pediatrics Reports, 2016, 4, 74-83.	1.7	0
149	Cancer of the vulva in Burkina Faso: a hospital-based case series. Infectious Agents and Cancer, 2016, 11, 33.	1.2	6
150	Factors affecting HPV vaccine acceptance in west Austria: Do we need to revise the current immunization scheme?. Papillomavirus Research (Amsterdam, Netherlands), 2016, 2, 173-177.	4.5	20
151	Pre-vaccine era cervical human papillomavirus infection among screening population of women in west Austria. BMC Public Health, 2016, 16, 889.	1.2	8
152	Human papillomavirus prevalence in unvaccinated heterosexual males following a national female vaccination program. Journal of Infectious Diseases, 2017, 215, jiw530.	1.9	28
153	A phase III clinical study to compare the immunogenicity and safety of the 9-valent and quadrivalent HPV vaccines in men. Vaccine, 2016, 34, 4205-4212.	1.7	68

#	ARTICLE	IF	CITATIONS
154	Primary Prevention of HPV through Vaccination: Update on the Current Global Status. <i>Current Obstetrics and Gynecology Reports</i> , 2016, 5, 210-224.	0.3	34
155	A cohort study of cervical screening using partial HPV typing and cytology triage. <i>International Journal of Cancer</i> , 2016, 139, 2606-2615.	2.3	68
156	9-Valent human papillomavirus recombinant vaccine (Gardasil® 9): a guide to its use in the EU. <i>Drugs and Therapy Perspectives</i> , 2016, 32, 414-421.	0.3	1
157	Epidemiology and Early Detection of Cervical Cancer. <i>Oncology Research and Treatment</i> , 2016, 39, 501-506.	0.8	51
158	Knowledge, attitudes and awareness of the human papillomavirus amongst primary care practice nurses: an evaluation of current training in England. <i>Journal of Public Health</i> , 2017, 39, 601-608.	1.0	20
159	Safety Profile of the 9-Valent HPV Vaccine: A Combined Analysis of 7 Phase III Clinical Trials. <i>Pediatrics</i> , 2016, 138, .	1.0	84
160	Risk of Delayed Human Papillomavirus Vaccination in Inner-City Adolescent Women. <i>Journal of Infectious Diseases</i> , 2016, 214, 1952-1960.	1.9	12
161	Variability of high risk HPV genotypes among HIV infected women in Mwanza, Tanzania- the need for evaluation of current vaccine effectiveness in developing countries. <i>Infectious Agents and Cancer</i> , 2016, 11, 49.	1.2	11
162	HPV Vaccination: Attitude and Knowledge among German Gynecologists. <i>Geburtshilfe Und Frauenheilkunde</i> , 2016, 76, 1074-1080.	0.8	1
163	Vaccination to Prevent Cancer. <i>North Carolina Medical Journal</i> , 2016, 77, 337-340.	0.1	1
165	Change Suboptimal Tactics and Promote a National Mandatory Human Papillomavirus Vaccination Program. <i>Journal of Lower Genital Tract Disease</i> , 2016, 20, 348-351.	0.9	1
166	Centers for Disease Control and Prevention 2015 Human Papillomavirus Vaccine Recommendations for Sexually Assaulted Patients: A Review and Update. <i>Journal of Forensic Nursing</i> , 2016, 12, 160-166.	0.2	0
167	Effect of HIV Infection on Human Papillomavirus Types Causing Invasive Cervical Cancer in Africa. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2016, 73, 332-339.	0.9	77
168	Rational Design of Peptide Vaccines against Multiple Types of Human Papillomavirus. <i>Cancer Informatics</i> , 2016, 15s1, CIN.S39071.	0.9	19
169	Age-specific prevalence of HPV 16/18 genotypes in cervical cancer: A systematic review and meta-analysis. <i>International Journal of Cancer</i> , 2016, 138, 2795-2803.	2.3	64
170	Cervical Infection With Vaccine-Associated Human Papillomavirus (HPV) Genotypes as a Predictor of Acquisition and Clearance of Other HPV Infections. <i>Journal of Infectious Diseases</i> , 2016, 214, 676-684.	1.9	9
171	Estimating the cost-effectiveness profile of a universal vaccination programme with a nine-valent HPV vaccine in Austria. <i>BMC Infectious Diseases</i> , 2016, 16, 153.	1.3	38
172	Human papillomavirus detection in cervical neoplasia attributed to 12 high-risk human papillomavirus genotypes by region. <i>Papillomavirus Research (Amsterdam, Netherlands)</i> , 2016, 2, 61-69.	4.5	30

#	ARTICLE	IF	CITATIONS
173	Should we lower the age for routine HPV vaccination in the United States?. Preventive Medicine, 2016, 89, 334-336.	1.6	0
174	Impact of HPV vaccination on anogenital warts and respiratory papillomatosis. Human Vaccines and Immunotherapeutics, 2016, 12, 1357-1362.	1.4	27
176	Monitoring the impact of HPV vaccine in males—Considerations and challenges. Papillomavirus Research (Amsterdam, Netherlands), 2016, 2, 106-111.	4.5	20
177	HPV infection and vaccination in Systemic Lupus Erythematosus patients: what we really should know. Pediatric Rheumatology, 2016, 14, 12.	0.9	31
178	Response letter regarding the letter to the editors by Brown et al.. Human Vaccines and Immunotherapeutics, 2016, 12, 1-4.	1.4	7
179	The potential impact of prophylactic human papillomavirus vaccination on oropharyngeal cancer. Cancer, 2016, 122, 2313-2323.	2.0	72
180	Positivity and incidence of human papillomavirus in women attending gynecological department of a major comprehensive hospital in Kunming, China 2012–2014. Journal of Medical Virology, 2016, 88, 703-711.	2.5	8
181	High Risk Human Papillomavirus Infection of the Foreskin in Asymptomatic Men and Patients with Phimosis. Journal of Urology, 2016, 195, 1784-1789.	0.2	24
182	Knowledge of human papillomavirus and the human papillomavirus vaccine in European adolescents: a systematic review. Sexually Transmitted Infections, 2016, 92, 474-479.	0.8	70
183	Why don't adolescents finish the HPV vaccine series? A qualitative study of parents and providers. Human Vaccines and Immunotherapeutics, 2016, 12, 1528-1535.	1.4	26
184	Health and Economic Impact of Switching from a 4-Valent to a 9-Valent HPV Vaccination Program in the United States. Journal of the National Cancer Institute, 2016, 108, djv282.	3.0	74
185	Human papillomavirus vaccination in HIV-infected women: need for increased coverage. Expert Review of Vaccines, 2016, 15, 105-117.	2.0	26
186	Public health value of universal HPV vaccination. Critical Reviews in Oncology/Hematology, 2016, 97, 157-167.	2.0	46
187	Global Delivery of Human Papillomavirus Vaccines. Pediatric Clinics of North America, 2016, 63, 81-95.	0.9	29
188	Triage of HPV positive women in cervical cancer screening. Journal of Clinical Virology, 2016, 76, S49-S55.	1.6	236
189	Cervical cancer screening of HPV vaccinated populations: Cytology, molecular testing, both or none. Journal of Clinical Virology, 2016, 76, S62-S68.	1.6	72
190	A randomized intervention study to evaluate whether electronic messaging can increase human papillomavirus vaccine completion and knowledge among college students. Journal of American College Health, 2016, 64, 269-278.	0.8	53
191	Prevention of cervical cancer: journey to develop the first human papillomavirus virus-like particle vaccine and the next generation vaccine. Current Opinion in Chemical Biology, 2016, 32, 34-47.	2.8	50

#	ARTICLE	IF	CITATIONS
192	The impact and cost-effectiveness of nonavalent HPV vaccination in the United States: Estimates from a simplified transmission model. <i>Human Vaccines and Immunotherapeutics</i> , 2016, 12, 1363-1372.	1.4	37
193	Clinical Cancer Advances 2016: Annual Report on Progress Against Cancer From the American Society of Clinical Oncology. <i>Journal of Clinical Oncology</i> , 2016, 34, 987-1011.	0.8	141
194	Prevalence of HPV After Introduction of the Vaccination Program in the United States. <i>Pediatrics</i> , 2016, 137, e20151968.	1.0	262
195	Current therapeutic vaccination and immunotherapy strategies for HPV-related diseases. <i>Human Vaccines and Immunotherapeutics</i> , 2016, 12, 1418-1429.	1.4	70
196	Cervical HPV natural history among young Western Cape, South African women: The randomized control EVRI Trial. <i>Journal of Infection</i> , 2016, 72, 60-69.	1.7	6
197	Prevalence of Human Papillomavirus Genotypes Among Women With High-Grade Cervical Lesions in Beijing, China. <i>Medicine (United States)</i> , 2016, 95, e2555.	0.4	10
198	Identification of potential missed opportunities for human papillomavirus (HPV) vaccination in women referred to an academic colposcopy clinic for evaluation of abnormal cervical cytology. <i>Human Vaccines and Immunotherapeutics</i> , 2016, 12, 1639-1645.	1.4	2
199	Impact and Cost-effectiveness of 3 Doses of 9-Valent Human Papillomavirus (HPV) Vaccine Among US Females Previously Vaccinated With 4-Valent HPV Vaccine. <i>Journal of Infectious Diseases</i> , 2016, 213, 1694-1700.	1.9	32
200	Prophylactic HPV vaccination and anal cancer. <i>Human Vaccines and Immunotherapeutics</i> , 2016, 12, 1348-1351.	1.4	35
201	Deconstructing the measure of vaccine efficacy against disease irrespective of HPV in HPV vaccine clinical trials. <i>Contemporary Clinical Trials</i> , 2016, 47, 254-258.	0.8	4
202	Estimating human papillomavirus vaccination coverage among young women in Victoria and reasons for non-vaccination. <i>Sexual Health</i> , 2016, 13, 190.	0.4	5
203	Secular trends of HPV genotypes in invasive cervical cancer in Cali, Colombia 1950-1999. <i>Cancer Epidemiology</i> , 2016, 40, 173-178.	0.8	1
204	Use of the nonavalent HPV vaccine in individuals previously fully or partially vaccinated with bivalent or quadrivalent HPV vaccines. <i>Vaccine</i> , 2016, 34, 757-761.	1.7	31
205	The paradigm shift in cervical cancer screening in Germany. <i>Archives of Gynecology and Obstetrics</i> , 2016, 293, 3-4.	0.8	6
206	Anti-Infectious Human Vaccination in Historical Perspective. <i>International Reviews of Immunology</i> , 2016, 35, 260-290.	1.5	18
207	Impact of 2-, 4- and 9-valent HPV vaccines on morbidity and mortality from cervical cancer. <i>Human Vaccines and Immunotherapeutics</i> , 2016, 12, 1332-1342.	1.4	29
209	Human Papillomavirus Vaccination of Boys and Extended Catch-up Vaccination: Effects on the Resilience of Programs. <i>Journal of Infectious Diseases</i> , 2016, 213, 199-205.	1.9	56
210	Seroprevalence of 9 Human Papillomavirus Types in the United States, 2005-2006. <i>Journal of Infectious Diseases</i> , 2016, 213, 191-198.	1.9	42

#	ARTICLE	IF	CITATIONS
211	HPV-FASTER: broadening the scope for prevention of HPV-related cancer. <i>Nature Reviews Clinical Oncology</i> , 2016, 13, 119-132.	12.5	154
212	Mechanistic and Technical Challenges in Studying the Human Microbiome and Cancer Epidemiology. <i>Technology in Cancer Research and Treatment</i> , 2017, 16, 150-158.	0.8	7
213	Human papillomavirus molecular biology. <i>Mutation Research - Reviews in Mutation Research</i> , 2017, 772, 3-12.	2.4	146
214	An estimate of the public health impact and cost-effectiveness of universal vaccination with a 9-valent HPV vaccine in Germany. <i>Expert Review of Pharmacoeconomics and Outcomes Research</i> , 2017, 17, 85-98.	0.7	36
215	Comparative seroepidemiology of genital human papillomavirus infections in the general population in Singapore. <i>Public Health</i> , 2017, 142, 1-3.	1.4	0
216	Clinical management of genital chronic GvHD. <i>Bone Marrow Transplantation</i> , 2017, 52, 803-810.	1.3	39
217	Skin Cancer: Epidemiology, Disease Burden, Pathophysiology, Diagnosis, and Therapeutic Approaches. <i>Dermatology and Therapy</i> , 2017, 7, 5-19.	1.4	286
218	Overview of the benefits and potential issues of the nonavalent <sc>HPV</sc> vaccine. <i>International Journal of Gynecology and Obstetrics</i> , 2017, 136, 258-265.	1.0	18
219	Listening to each other: Infectious disease and cancer immunology. <i>Science Immunology</i> , 2017, 2, .	5.6	25
220	Disease burden of human papillomavirus infection in the Netherlands, 1989â€“2014: the gap between females and males is diminishing. <i>Cancer Causes and Control</i> , 2017, 28, 203-214.	0.8	22
221	Vaccine-related serious adverse events might have been under-recognized in the pivotal HPV vaccine randomized trial. <i>Clinical Rheumatology</i> , 2017, 36, 975-975.	1.0	4
222	Molecular tests potentially improving HPV screening and genotyping for cervical cancer prevention. <i>Expert Review of Molecular Diagnostics</i> , 2017, 17, 379-391.	1.5	55
223	Performance and Diagnostic Accuracy of a Urine-Based Human Papillomavirus Assay in a Referral Population. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2017, 26, 1053-1059.	1.1	34
224	Stop codon mutagenesis for homogenous expression of human papillomavirus L1 protein in <i>Escherichia coli</i> . <i>Protein Expression and Purification</i> , 2017, 133, 110-120.	0.6	7
225	Human papillomavirus (HPV) in young women in Britain: Population-based evidence of the effectiveness of the bivalent immunisation programme and burden of quadrivalent and 9-valent vaccine types. <i>Papillomavirus Research (Amsterdam, Netherlands)</i> , 2017, 3, 36-41.	4.5	16
226	No evidence for cross-protection of the HPV-16/18 vaccine against HPV-6/11 positivity in female STI clinic visitors. <i>Journal of Infection</i> , 2017, 74, 393-400.	1.7	19
227	The Need to Optimize Adolescent Immunization. <i>Pediatrics</i> , 2017, 139, .	1.0	41
228	Introduction of molecular HPV testing as the primary technology in cervical cancer screening: Acting on evidence to change the current paradigm. <i>Preventive Medicine</i> , 2017, 98, 5-14.	1.6	87

#	ARTICLE	IF	CITATIONS
229	Human papilloma virus and lupus: the virus, the vaccine and the disease. <i>Current Opinion in Rheumatology</i> , 2017, 29, 331-342.	2.0	40
230	Management of Para-aortic Lymph Node Disease in Patients With Cervical Cancer. <i>International Journal of Gynecological Cancer</i> , 2017, 27, 543-549.	1.2	3
231	Ranpirnase Eradicates Human Papillomavirus in Cultured Cells and Heals Anogenital Warts in a Phase I Study. <i>Antiviral Therapy</i> , 2017, 22, 247-255.	0.6	14
232	Human Papilloma Virus Infections in Men: Focus on Vaccination and Treatment Options. <i>Current Treatment Options in Infectious Diseases</i> , 2017, 9, 34-43.	0.8	0
233	Estimation of the overall burden of cancers, precancerous lesions, and genital warts attributable to 9-valent HPV vaccine types in women and men in Europe. <i>Infectious Agents and Cancer</i> , 2017, 12, 19.	1.2	76
234	Response to Dr. Hawkes letter regarding HPV vaccine serious adverse events. <i>Clinical Rheumatology</i> , 2017, 36, 2629-2630.	1.0	0
235	Antiangiogenics and immunotherapies in cervical cancer: an update and future's view. <i>Medical Oncology</i> , 2017, 34, 115.	1.2	14
236	Bacterially expressed human papillomavirus type 6 and 11 bivalent vaccine: Characterization, antigenicity and immunogenicity. <i>Vaccine</i> , 2017, 35, 3222-3231.	1.7	7
237	Cervical cancer: A global health crisis. <i>Cancer</i> , 2017, 123, 2404-2412.	2.0	790
238	Hispanic mothers' beliefs regarding HPV vaccine series completion in their adolescent daughters. <i>Health Education Research</i> , 2017, 32, cyw055.	1.0	15
239	The role of HPV vaccination in the prevention of anal dysplasia. <i>Seminars in Colon and Rectal Surgery</i> , 2017, 28, 106-110.	0.2	0
240	Two-dose schedules for human papillomavirus vaccine: Systematic review and meta-analysis. <i>Vaccine</i> , 2017, 35, 2892-2901.	1.7	46
241	The changing landscape of cervical screening-What does the future hold for primary care?. <i>European Journal of Cancer Care</i> , 2017, 26, e12693.	0.7	3
242	HPV vaccines "A review of the first decade. <i>Gynecologic Oncology</i> , 2017, 146, 196-204.	0.6	304
243	Human papillomavirus 9-valent vaccine for cancer prevention: a systematic review of the available evidence. <i>Epidemiology and Infection</i> , 2017, 145, 1962-1982.	1.0	51
244	Future prospects for new vaccines against sexually transmitted infections. <i>Current Opinion in Infectious Diseases</i> , 2017, 30, 77-86.	1.3	55
245	When Less is More. <i>Journal of the National Cancer Institute</i> , 2017, 109, djw240.	3.0	1
246	Potential impact of a nonavalent HPV vaccine on HPV related low-and high-grade cervical intraepithelial lesions: A referral hospital-based study in Sicily. <i>Human Vaccines and Immunotherapeutics</i> , 2017, 13, 1839-1843.	1.4	31

#	ARTICLE	IF	CITATIONS
247	Evaluation of Type Replacement Following HPV16/18 Vaccination: Pooled Analysis of Two Randomized Trials. <i>Journal of the National Cancer Institute</i> , 2017, 109, djw300.	3.0	43
248	Spontaneous and Vaccine-Induced Clearance of Mus Musculus Papillomavirus 1 Infection. <i>Journal of Virology</i> , 2017, 91, .	1.5	23
249	Seropositivity to non-vaccine incorporated genotypes induced by the bivalent and quadrivalent HPV vaccines: A systematic review and meta-analysis. <i>Vaccine</i> , 2017, 35, 3922-3929.	1.7	21
250	Cervical cancer screening in the era of HPV vaccination: A review of shifting paradigms in cytopathology. <i>Diagnostic Cytopathology</i> , 2017, 45, 903-914.	0.5	10
251	Genetic diversity of human papillomavirus types 35, 45 and 58 in cervical cancer in Brazil. <i>Archives of Virology</i> , 2017, 162, 2855-2860.	0.9	6
252	A review of the use of human papilloma virus (HPV) in cervical screening. <i>British Journal of Biomedical Science</i> , 2017, 74, 105-109.	1.2	5
253	Opportunities and Challenges: Human Papillomavirus and Cancer. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2017, 15, 726-729.	2.3	2
255	Role of Human Papillomavirus in Vulvar Cancer. <i>Advances in Anatomic Pathology</i> , 2017, 24, 201-214.	2.4	43
256	Precision Medicine in Gynecology and Obstetrics. <i>Comprehensive Gynecology and Obstetrics</i> , 2017, , .	0.0	1
257	Adolescent human papillomavirus vaccination in the United States: Opportunities for integrating pharmacies into the immunization neighborhood. <i>Human Vaccines and Immunotherapeutics</i> , 2017, 13, 1844-1855.	1.4	19
259	Letter to the Editor in response to N Folschweiller, V Berlaimont, SR Skinner, CM Wheeler, N Karkada, F Struyf, M Ryser. Letter to the Editor in response to O.M. Bautista, A. Luxembourg. Deconstructing the measure of vaccine efficacy against disease irrespective of HPV in HPV vaccine clinical trials. <i>Contemp. Clin. Trials</i> (2016), doi: 10.1016/j.cct.2016.12.022. <i>Contemporary Clinical Trials</i> , 2017, 54, 105.	0.8	0
260	Retail Clinic Nurse Practitioner Knowledge, Barriers, and Practice Recommendations: Human Papillomavirus Vaccine. <i>Journal for Nurse Practitioners</i> , 2017, 13, e241-e244.	0.4	2
261	HPV serostatus pre- and post-vaccination in a randomized phase II preparedness trial among young Western Cape, South African women: The evri trial. <i>Papillomavirus Research (Amsterdam, Nl)</i> 10 Tf50 257 Td	0.0	0
262	Reproductive Health Screening in Women with Autoimmune Diseases. <i>Rheumatic Disease Clinics of North America</i> , 2017, 43, 161-171.	0.8	4
263	Effect of naturally acquired type-specific serum antibodies against human papillomavirus type 16 infection. <i>Journal of Clinical Virology</i> , 2017, 90, 64-69.	1.6	3
264	Human papillomavirus in cervical cancer and oropharyngeal cancer: One cause, two diseases. <i>Cancer</i> , 2017, 123, 2219-2229.	2.0	284
265	Response to Vaccine-related serious adverse events might have been under-recognized in the pivotal HPV vaccine randomized trial. <i>Clinical Rheumatology</i> , 2017, 36, 1691-1692.	1.0	2
266	Prevalence of Human Papillomavirus infection among Chilean women from 2012 to 2016. <i>Journal of Medical Virology</i> , 2017, 89, 1646-1653.	2.5	4

#	ARTICLE	IF	CITATIONS
267	The prevalence of HPV infections in HPV-unvaccinated women from the general population. <i>Apmis</i> , 2017, 125, 585-595.	0.9	7
268	Impact of baseline covariates on the immunogenicity of the 9-valent HPV vaccine – A combined analysis of five phase III clinical trials. <i>Papillomavirus Research (Amsterdam, Netherlands)</i> , 2017, 3, 105-115.	4.5	22
269	Immunotherapy against cancer-related viruses. <i>Cell Research</i> , 2017, 27, 59-73.	5.7	101
270	Reactivation of Latent HPV Infections After Renal Transplantation. <i>American Journal of Transplantation</i> , 2017, 17, 1563-1573.	2.6	44
271	Detection of HPV subtypes by mass spectrometry in FFPE tissue specimens: a reliable tool for routine diagnostics. <i>Journal of Clinical Pathology</i> , 2017, 70, 417-423.	1.0	16
273	Different Challenges in Eliminating HPV16 Compared to Other Types: A Modeling Study. <i>Journal of Infectious Diseases</i> , 2017, 216, 336-344.	1.9	20
274	9-Valent human papillomavirus vaccine: a review of the clinical development program. <i>Expert Review of Vaccines</i> , 2017, 16, 1119-1139.	2.0	41
275	Cervical Screening: History, Current Algorithms, and Future Directions. , 2017, , 45-65.		2
276	Crystal Structures of Two Immune Complexes Identify Determinants for Viral Infectivity and Type-Specific Neutralization of Human Papillomavirus. <i>MBio</i> , 2017, 8, .	1.8	20
277	A novel candidate HPV vaccine: MS2 phage VLP displaying a tandem HPV L2 peptide offers similar protection in mice to Gardasil-9. <i>Antiviral Research</i> , 2017, 147, 116-123.	1.9	45
278	Estimating the epidemiological burden of pathologies associated with 9 human papillomavirus genotypes in Spain: Literature review. <i>Vacunas (English Edition)</i> , 2017, 18, 36-42.	0.3	0
279	HPV prevalence in vulvar cancer in Austria. <i>Wiener Klinische Wochenschrift</i> , 2017, 129, 805-809.	1.0	18
280	Response to Harper and De Mars, HPV vaccines: A review of the first decade. <i>Gynecologic Oncology Reports</i> , 2017, 22, 113-114.	0.3	3
281	Human Papillomavirus Vaccination and Pap Smear Uptake Among Young Women in the United States: Role of Provider and Patient. <i>Journal of Women's Health</i> , 2017, 26, 1114-1122.	1.5	11
282	Ten-year follow-up of human papillomavirus vaccine efficacy against the most stringent cervical neoplasia end-point – registry-based follow-up of three cohorts from randomized trials. <i>BMJ Open</i> , 2017, 7, e015867.	0.8	67
283	Immunotherapy for triple-negative breast cancer: Existing challenges and exciting prospects. <i>Drug Resistance Updates</i> , 2017, 32, 1-15.	6.5	132
285	Research in Gynaecological Oncology. , 0, , 255-259.		0
286	Risk Prediction of Cervical Cancer and Precancers by Type-Specific Human Papillomavirus: Evidence from a Population-Based Cohort Study in China. <i>Cancer Prevention Research</i> , 2017, 10, 745-751.	0.7	16



#	ARTICLE	IF	CITATIONS
287	Burden of HPV-caused cancers in Denmark and the potential effect of HPV-vaccination. <i>Vaccine</i> , 2017, 35, 5939-5945.	1.7	8
288	Cost-effectiveness of HPV vaccination in the context of high cervical cancer incidence and low screening coverage. <i>Vaccine</i> , 2017, 35, 6329-6335.	1.7	9
289	Tumour virus vaccines: hepatitis B virus and human papillomavirus. <i>Philosophical Transactions of the Royal Society B: Biological Sciences</i> , 2017, 372, 20160268.	1.8	48
290	Human papilloma virus (HPV) vaccination: Questions and answers. <i>Canadian Pharmacists Journal</i> , 2017, 150, 306-315.	0.4	10
291	Human Papillomavirus and HPV Vaccines. <i>Pediatrics in Review</i> , 2017, 38, 443-445.	0.2	2
292	Final efficacy, immunogenicity, and safety analyses of a nine-valent human papillomavirus vaccine in women aged 16–26 years: a randomised, double-blind trial. <i>Lancet, The</i> , 2017, 390, 2143-2159.	6.3	314
293	Nine-valent human papillomavirus vaccine: great science, but will it save lives?. <i>Lancet, The</i> , 2017, 390, 2123-2124.	6.3	2
294	Current status and future prospects for human papillomavirus vaccines. <i>Archives of Pharmacal Research</i> , 2017, 40, 1050-1063.	2.7	40
295	The health and economic impact of scaling cervical cancer prevention in 50 low- and lower-middle-income countries. <i>International Journal of Gynecology and Obstetrics</i> , 2017, 138, 47-56.	1.0	50
296	Looking beyond human papillomavirus (HPV) genotype 16 and 18: Defining HPV genotype distribution in cervical cancers in Australia prior to vaccination. <i>International Journal of Cancer</i> , 2017, 141, 1576-1584.	2.3	51
297	Serious adverse events after HPV vaccination: a critical review of randomized trials and post-marketing case series. <i>Clinical Rheumatology</i> , 2017, 36, 2169-2178.	1.0	27
298	Characterization of an Escherichia coli -derived human papillomavirus type 16 and 18 bivalent vaccine. <i>Vaccine</i> , 2017, 35, 4637-4645.	1.7	32
299	Distribution of Human Papillomavirus Genotypes among Women in Mashhad, Iran. <i>Intervirolgy</i> , 2017, 60, 38-42.	1.2	11
300	A population-based study of cervical cytology findings and human papillomavirus infection in a suburban area of Thailand. <i>Gynecologic Oncology Reports</i> , 2017, 21, 73-77.	0.3	12
301	HPV vaccination of immunocompromised hosts. <i>Papillomavirus Research (Amsterdam, Netherlands)</i> , 2017, 4, 35-38.	4.5	51
304	Preventive therapy for cancer. <i>Lancet Oncology, The</i> , 2017, 18, e472-e482.	5.1	81
305	Primary care team- and clinic level factors affecting HPV vaccine uptake. <i>Vaccine</i> , 2017, 35, 4540-4547.	1.7	23
306	Determinants of Human Papillomavirus Vaccination Intention Among Female Sex Workers in Amsterdam, the Netherlands. <i>Sexually Transmitted Diseases</i> , 2017, 44, 756-762.	0.8	4

#	ARTICLE	IF	CITATIONS
307	Intention-to-prevent analyses for estimating human papillomavirus vaccine efficacy in clinical studies. Contemporary Clinical Trials Communications, 2017, 7, 189-193.	0.5	2
308	Cervical cancer control in HIV-infected women: Past, present and future. Gynecologic Oncology Reports, 2017, 21, 101-108.	0.3	114
309	Progress in HPV vaccination in low- and lower-middle-income countries. International Journal of Gynecology and Obstetrics, 2017, 138, 7-14.	1.0	61
312	HPV knowledge and vaccination rates in college-aged males. Nurse Practitioner, 2017, 42, 49-53.	0.2	1
313	Foreword. Family and Community Health, 2017, 40, 99-100.	0.5	0
314	Human Papilloma Virus Vaccination and Incidence of Ocular Surface Squamous Neoplasia. International Ophthalmology Clinics, 2017, 57, 57-74.	0.3	7
315	Antibody persistence and evidence of immune memory at 5 years following administration of the 9-valent HPV vaccine. Vaccine, 2017, 35, 5050-5057.	1.7	28
317	HPV Vaccination: Are We Meeting Our Targets in Cervical Cancer Prevention?. Current Obstetrics and Gynecology Reports, 2017, 6, 219-227.	0.3	1
318	4-Valent Human Papillomavirus (4vHPV) Vaccine in Preadolescents and Adolescents After 10 Years. Pediatrics, 2017, 140, .	1.0	51
320	Vaccine-Preventable Diseases and the Vaccines That Prevent Them. , 2017, , 101-168.		0
321	Pediatric Vaccines and Vaccinations. , 2017, , .		1
324	Expanded strain coverage for a highly successful public health tool: Prophylactic 9-valent human papillomavirus vaccine. Human Vaccines and Immunotherapeutics, 2017, 13, 2280-2291.	1.4	19
325	Cervical cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Annals of Oncology, 2017, 28, iv72-iv83.	0.6	604
326	HPV-vaccinatie. Bijblijven (Amsterdam, Netherlands), 2017, 33, 29-40.	0.0	0
327	Factors associated with parental reasons for "no-intent" to vaccinate female adolescents with human papillomavirus vaccine: National Immunization Survey - Teen 2008-2012. BMC Pediatrics, 2017, 17, 52.	0.7	26
328	hrHPV E5 oncoprotein: immune evasion and related immunotherapies. Journal of Experimental and Clinical Cancer Research, 2017, 36, 71.	3.5	46
329	The feminization of HPV: How science, politics, economics and gender norms shaped U.S. HPV vaccine implementation. Papillomavirus Research (Amsterdam, Netherlands), 2017, 3, 142-148.	4.5	99
332	DIA's Adaptive Design Scientific Working Group (ADSWG): Best Practices Case Studies for "Less Well-understood" Adaptive Designs. Therapeutic Innovation and Regulatory Science, 2017, 51, 77-88.	0.8	7

#	ARTICLE	IF	CITATIONS
333	Interventions to close the divide for women with breast and cervical cancer between low-income and middle-income countries and high-income countries. <i>Lancet, The</i> , 2017, 389, 861-870.	6.3	171
334	Optimal Cervical Cancer Screening in Women Vaccinated Against Human Papillomavirus. <i>Journal of the National Cancer Institute</i> , 2017, 109, djw216.	3.0	72
335	Epigenetic Treatment of Persistent Viral Infections. <i>Drug Development Research</i> , 2017, 78, 24-36.	1.4	17
336	Design of a long-term follow-up effectiveness, immunogenicity and safety study of women who received the 9-valent human papillomavirus vaccine. <i>Contemporary Clinical Trials</i> , 2017, 52, 54-61.	0.8	12
337	The whole story: a systematic review of economic evaluations of HPV vaccination including non-cervical HPV-associated diseases. <i>Expert Review of Vaccines</i> , 2017, 16, 361-375.	2.0	16
338	The global incidence of lip, oral cavity, and pharyngeal cancers by subsite in 2012. <i>Ca-A Cancer Journal for Clinicians</i> , 2017, 67, 51-64.	157.7	516
339	Adherence to ACIP Recommendation for Human Papillomavirus Vaccine Among US Adolescent Girls. <i>Journal of Community Health</i> , 2017, 42, 385-389.	1.9	9
340	Continuing rise in oropharyngeal cancer in a high HPV prevalence area: A Danish population-based study from 2011 to 2014. <i>European Journal of Cancer</i> , 2017, 70, 75-82.	1.3	115
341	Developments in L2-based human papillomavirus (HPV) vaccines. <i>Virus Research</i> , 2017, 231, 166-175.	1.1	61
342	Cervical cancer screening in women vaccinated against human papillomavirus infection: Recommendations from a consensus conference. <i>Preventive Medicine</i> , 2017, 98, 21-30.	1.6	49
343	Metastatic Anal Cancer and Novel Agents. <i>Surgical Oncology Clinics of North America</i> , 2017, 26, 133-142.	0.6	7
344	Human Immunodeficiency Virus/AIDS, Human Papillomavirus, and Anal Cancer. <i>Surgical Oncology Clinics of North America</i> , 2017, 26, 17-31.	0.6	64
345	Human Papillomavirus and Its Testing Assays, Cervical Cancer Screening, and Vaccination. <i>Advances in Clinical Chemistry</i> , 2017, 81, 135-192.	1.8	13
346	Catheter-based renal denervation for treatment of hypertension. <i>Lancet, The</i> , 2017, 390, 2124-2126.	6.3	10
347	Why Human Papillomavirus Acute Infections Matter. <i>Viruses</i> , 2017, 9, 293.	1.5	49
348	Attitudes towards Human Papilloma Virus Vaccination in the Latin American Andean Region. <i>Healthcare (Switzerland)</i> , 2017, 5, 55.	1.0	5
349	Lower Incidence of Cervical Intraepithelial Neoplasia among Young Women with Human Papillomavirus Vaccination in Miyagi, Japan. <i>Tohoku Journal of Experimental Medicine</i> , 2017, 243, 329-334.	0.5	12
350	Co-carcinogenesis: Human Papillomaviruses, Coal Tar Derivatives, and Squamous Cell Cervical Cancer. <i>Frontiers in Microbiology</i> , 2017, 8, 2253.	1.5	13

#	ARTICLE	IF	CITATIONS
351	Clinician's Update on the Benign, Premalignant, and Malignant Skin Tumours of the Vulva: The Dermatologist's View. <i>International Scholarly Research Notices</i> , 2017, 2017, 1-10.	0.9	4
352	Safety of Human Papillomavirus 9-Valent Vaccine: A Meta-Analysis of Randomized Trials. <i>Journal of Immunology Research</i> , 2017, 2017, 1-6.	0.9	15
353	Cost analysis of Human Papillomavirus-related cervical diseases and genital warts in Swaziland. <i>PLoS ONE</i> , 2017, 12, e0177762.	1.1	10
354	Lessons learnt from human papillomavirus (HPV) vaccination in 45 low- and middle-income countries. <i>PLoS ONE</i> , 2017, 12, e0177773.	1.1	81
355	Expression optimization of a cell membrane-penetrating human papillomavirus type 16 therapeutic vaccine candidate in <i>Nicotiana benthamiana</i> . <i>PLoS ONE</i> , 2017, 12, e0183177.	1.1	18
356	Modelling the effects of quadrivalent Human Papillomavirus (HPV) vaccination in Puerto Rico. <i>PLoS ONE</i> , 2017, 12, e0184540.	1.1	5
357	Cancer incidence in Germany attributable to human papillomavirus in 2013. <i>BMC Cancer</i> , 2017, 17, 682.	1.1	19
358	Cost-effectiveness analysis of the nine-valent HPV vaccine in Italy. <i>Cost Effectiveness and Resource Allocation</i> , 2017, 15, 11.	0.6	32
359	Safety and Immunogenicity of a 9-Valent Human Papillomavirus Vaccine Administered to 9- to 15-Year-Old Japanese Girls. <i>Japanese Journal of Infectious Diseases</i> , 2017, 70, 368-373.	0.5	11
360	Epidemiology of cervical human papillomavirus (HPV) infection and squamous intraepithelial lesions (SIL) among a cohort of HIV-infected and uninfected Ghanaian women. <i>BMC Cancer</i> , 2017, 17, 688.	1.1	43
363	Elimination of Cancer Health Disparities through the Acceleration of HPV Vaccines and Vaccinations: A Simplified Version of the President's Cancer Panel Report on HPV Vaccinations. <i>Journal of Vaccines &amp; Vaccination</i> , 2017, 08, .	0.3	12
364	Ethnic Variations in Perception of Human Papillomavirus and its Vaccination among Young Women in Nepal. <i>Journal of College of Medical Sciences-Nepal</i> , 2017, 7, 647-658.	0.2	8
365	Human papillomavirus vaccination: the population impact. <i>F1000Research</i> , 2017, 6, 866.	0.8	73
366	Anal intraepithelial neoplasia: A review of diagnosis and management. <i>World Journal of Gastrointestinal Oncology</i> , 2017, 9, 50.	0.8	92
367	Comprehensive Human Papillomavirus Genotyping in Cervical Squamous Cell Carcinomas and Its Relevance to Cervical Cancer Prevention in Malawian Women. <i>Journal of Global Oncology</i> , 2017, 3, 227-234.	0.5	10
368	Cervical Precancer Treatment in Low- and Middle-Income Countries: A Technology Overview. <i>Journal of Global Oncology</i> , 2017, 3, 400-408.	0.5	37
369	Chemoprevention Trials. , 2017, , .		1
370	Hospitalization burden associated with malignant neoplasia and in situ carcinoma in vulva and vagina during a 5-year period (2009-2013) in Spain: An epidemiological study. <i>Papillomavirus Research (Amsterdam, Netherlands)</i> , 2018, 5, 80-86.	4.5	3

#	ARTICLE	IF	CITATIONS
371	Prophylactic Vaccines for Nonviral Cancers. <i>Annual Review of Cancer Biology</i> , 2018, 2, 195-211.	2.3	8
372	US Health Care Clinicians' Knowledge, Attitudes, and Practices Regarding Human Papillomavirus Vaccination: A Qualitative Systematic Review. <i>Academic Pediatrics</i> , 2018, 18, S53-S65.	1.0	50
373	Assessment of treatment factors and clinical outcomes in cervical cancer in older women compared to women under 65 years old. <i>Journal of Geriatric Oncology</i> , 2018, 9, 516-519.	0.5	20
374	Long-term incidence trends of HPV-related cancers, and cases preventable by HPV vaccination: a registry-based study in Norway. <i>BMJ Open</i> , 2018, 8, e019005.	0.8	52
375	Opportunities and challenges for human papillomavirus vaccination in cancer. <i>Nature Reviews Cancer</i> , 2018, 18, 240-254.	12.8	224
376	Ten Years of Human Papillomavirus Vaccination in the United States. <i>Academic Pediatrics</i> , 2018, 18, S3-S10.	1.0	128
377	Update in Pediatric Infectious Disease. , 2018, , 349-368.		0
378	Progress in preventive therapy for cancer: a reminiscence and personal viewpoint. <i>British Journal of Cancer</i> , 2018, 118, 1155-1161.	2.9	12
379	Determinants of the receipt of the 9-valent human papillomavirus vaccine in the first year after introduction in North Carolina. <i>Vaccine</i> , 2018, 36, 1310-1315.	1.7	0
380	Impacts of human papillomavirus vaccination for different populations: A modeling study. <i>International Journal of Cancer</i> , 2018, 143, 1086-1092.	2.3	18
381	Evaluation of HPV-16 and HPV-18 specific antibody measurements in saliva collected in oral rinses and merocel® sponges. <i>Vaccine</i> , 2018, 36, 2705-2711.	1.7	16
382	Prevalence and Incidence of Anal and Cervical High-Risk Human Papillomavirus (HPV) Types Covered by Current HPV Vaccines Among HIV-Infected Women in the SUN Study. <i>Journal of Infectious Diseases</i> , 2018, 217, 1544-1552.	1.9	17
383	Vaccines and the Prevention of Dermatologic Diseases. , 2018, , 1109-1124.		0
386	Immunogenicity of HPV prophylactic vaccines: Serology assays and their use in HPV vaccine evaluation and development. <i>Vaccine</i> , 2018, 36, 4792-4799.	1.7	60
387	Human Papillomaviruses. , 2018, , 1101-1105.e1.		0
388	Human Papilloma Virus Vaccination Among Adolescents in a Community Clinic Before and After Intervention. <i>Journal of Community Health</i> , 2018, 43, 455-458.	1.9	3
389	Evaluation of HPV type replacement in unvaccinated and vaccinated adolescent females: A post-hoc analysis of a community-randomized clinical trial (II). <i>International Journal of Cancer</i> , 2018, 142, 2491-2500.	2.3	28
390	On surmounting the barriers to HPV vaccination: we can do better. <i>Annals of Medicine</i> , 2018, 50, 209-225.	1.5	38

#	ARTICLE	IF	CITATIONS
391	Adapting cervical cancer screening for women vaccinated against human papillomavirus infections: The value of stratifying guidelines. <i>European Journal of Cancer</i> , 2018, 91, 68-75.	1.3	45
392	Very Low Prevalence of Vaccine Human Papillomavirus Types Among 18- to 35-Year Old Australian Women 9 Years Following Implementation of Vaccination. <i>Journal of Infectious Diseases</i> , 2018, 217, 1590-1600.	1.9	110
393	Clinical and economic impact of school-based nonavalent human papillomavirus vaccine on women in Singapore: a transmission dynamic mathematical model analysis. <i>BJOG: an International Journal of Obstetrics and Gynaecology</i> , 2018, 125, 478-486.	1.1	15
394	Efficacy, immunogenicity, and safety of a 9-valent human papillomavirus vaccine in Latin American girls, boys, and young women. <i>Papillomavirus Research (Amsterdam, Netherlands)</i> , 2018, 5, 63-74.	4.5	22
395	Using narrative intervention for HPV vaccine behavior change among Khmer mothers and daughters: A pilot RCT to examine feasibility, acceptability, and preliminary effectiveness. <i>Applied Nursing Research</i> , 2018, 40, 51-60.	1.0	29
396	Therapeutic vaccines for high-risk HPV-associated diseases. <i>Papillomavirus Research (Amsterdam, Netherlands)</i> , 2018, 5, 75-84.	4.5	163
397	Safety of Human Papillomavirus Vaccines: An Updated Review. <i>Drug Safety</i> , 2018, 41, 329-346.	1.4	86
398	A systematic review and meta-analysis on the attribution of human papillomavirus (HPV) in neuroendocrine cancers of the cervix. <i>Gynecologic Oncology</i> , 2018, 148, 422-429.	0.6	81
399	Therapeutic DNA Vaccines for Human Papillomavirus and Associated Diseases. <i>Human Gene Therapy</i> , 2018, 29, 971-996.	1.4	44
400	A Physician's Recommendation for Human Papillomavirus Vaccination. <i>Pediatric Infectious Disease Journal</i> , 2018, 37, e222-e225.	1.1	2
401	The Direct Medical Costs of Diseases Associated with Human Papillomavirus Infection in Manitoba, Canada. <i>Applied Health Economics and Health Policy</i> , 2018, 16, 195-205.	1.0	3
402	The role of human papillomavirus vaccines in cervical cancer: Prevention and treatment. <i>Critical Reviews in Oncology/Hematology</i> , 2018, 122, 92-97.	2.0	53
403	Vaginal and anal human papillomavirus infection and seropositivity among female sex workers in Amsterdam, the Netherlands: Prevalence, concordance and risk factors. <i>Journal of Infection</i> , 2018, 76, 393-405.	1.7	12
404	Human papillomavirus vaccination and the role of herd effects in future cancer control planning: a review. <i>Expert Review of Vaccines</i> , 2018, 17, 395-409.	2.0	19
405	Identifying populations most susceptible to get benefit from broadening the scope for prevention of cervical cancer: Example from Uruguay. <i>Papillomavirus Research (Amsterdam, Netherlands)</i> , 2018, 5, 122-127.	4.5	0
406	Síndrome posvacunal VPH. ¿Un espejismo clínic, o un nuevo modelo trágico de fibromialgia?. <i>Reumatología Clínica</i> , 2018, 14, 211-214.	0.2	8
407	Estimation of the individual residual risk of cervical cancer after vaccination with the nonavalent HPV vaccine. <i>Human Vaccines and Immunotherapeutics</i> , 2018, 14, 1800-1806.	1.4	9
408	Prevalence of <i>Trichomonas vaginalis</i> and Human papillomavirus in female sex workers in Central Veracruz, Mexico. <i>Revista Argentina De Microbiología</i> , 2018, 50, 351-358.	0.4	4

#	ARTICLE	IF	CITATIONS
409	Cervical screening in HPV-vaccinated populations. <i>Climacteric</i> , 2018, 21, 227-234.	1.1	8
410	Comment on: "Safety of Human Papillomavirus Vaccines: An Updated Review". <i>Drug Safety</i> , 2018, 41, 539-540.	1.4	1
411	Safety and perception: What are the greatest enemies of HPV vaccination programmes?. <i>Vaccine</i> , 2018, 36, 5424-5429.	1.7	22
412	Impact of gender-neutral or girls-only vaccination against human papillomavirus"Results of a community-randomized clinical trial (I). <i>International Journal of Cancer</i> , 2018, 142, 949-958.	2.3	42
413	Factors involved in human papillomavirus (HPV) vaccine hesitancy among women in the South-East Asian Region (SEAR) and Western Pacific Region (WPR): A scoping review. <i>Human Vaccines and Immunotherapeutics</i> , 2018, 14, 124-133.	1.4	30
414	Technologies for Making New Vaccines. , 2018, , 1283-1304.e7.		5
415	Population-based HPV vaccination programmes are safe and effective: 2017 update and the impetus for achieving better global coverage. <i>Best Practice and Research in Clinical Obstetrics and Gynaecology</i> , 2018, 47, 42-58.	1.4	72
416	Lessons learned from domestic and international human papillomavirus vaccination programs: a review. <i>American Journal of Obstetrics and Gynecology</i> , 2018, 218, 467-473.	0.7	11
418	Prevalence of Human Papillomavirus Genotypes and Abnormal Pap Smears Among Women in the Military Health System. <i>Journal of Community Health</i> , 2018, 43, 441-447.	1.9	7
419	Human-papillomavirus-related disease in pediatrics. <i>Current Opinion in Pediatrics</i> , 2018, 30, 169-174.	1.0	6
420	Prevalence and sociodemographic correlates of cervicovaginal human papillomavirus (HPV) carriage in a cross-sectional, multiethnic, community-based female Asian population. <i>Sexually Transmitted Infections</i> , 2018, 94, 277-283.	0.8	22
421	HPV vaccination. <i>Gynecologic Oncology</i> , 2018, 148, 3-4.	0.6	6
422	Vaccination Recommendations for Adults With Autoimmune Inflammatory Rheumatic Diseases in Latin America. <i>Journal of Clinical Rheumatology</i> , 2018, 24, 138-147.	0.5	8
423	Safety profile of the 9-valent human papillomavirus vaccine: assessment in prior quadrivalent HPV vaccine recipients and in men 16 to 26 years of age. <i>Human Vaccines and Immunotherapeutics</i> , 2018, 14, 396-403.	1.4	7
425	Non-invasive detection of HPV DNA in exfoliative samples from ophthalmic pterygium: a feasibility study. <i>Graefes' Archive for Clinical and Experimental Ophthalmology</i> , 2018, 256, 193-198.	1.0	6
426	HPV genotype profile in a Norwegian cohort with ASC-US and LSIL cytology with three year cumulative risk of high grade cervical neoplasia. <i>Gynecologic Oncology</i> , 2018, 148, 111-117.	0.6	9
427	HPV Vaccination Among Foreign-Born Women: Examining the National Health Interview Survey 2013-2015. <i>American Journal of Preventive Medicine</i> , 2018, 54, 20-27.	1.6	20
428	Progress in prophylactic human papillomavirus (HPV) vaccination in 2016: A literature review. <i>Vaccine</i> , 2018, 36, 5416-5423.	1.7	39

#	ARTICLE	IF	CITATIONS
429	Diagnosis of <i>Trichomonas vaginalis</i> using real-time polymerase chain reaction (PCR) among women at Institut Pasteur of Cte dlvoire. <i>African Journal of Microbiology Research</i> , 2018, 12, 988-993.	0.4	2
430	Cervical Cancer: Screening, Vaccination, and Preventive Strategies. , 2018, , .		0
431	From prevention to cure, repurposing anti-viral vaccines for cancer immunotherapy. <i>Biotarget</i> , 2018, 2, 20-20.	0.5	0
432	Joint Guideline of the OEGGG, AGO, AGK and Ã–GZ on the Diagnosis and Treatment of Cervical Intraepithelial Neoplasia and Appropriate Procedures When Cytological Specimens Are Unsatisfactory. <i>Geburtshilfe Und Frauenheilkunde</i> , 2018, 78, 1232-1244.	0.8	2
433	Recommendations for cervical cancer prevention and control in Ghana: public education and human papillomavirus vaccination. <i>Ghana Medical Journal</i> , 2018, 52, 94.	0.1	14
434	Autonomic dysfunction and HPV immunization: an overview. <i>Immunologic Research</i> , 2018, 66, 744-754.	1.3	38
435	Involvement of Human Papillomaviruses in Cervical Cancer. <i>Frontiers in Microbiology</i> , 2018, 9, 2896.	1.5	88
436	Ten years of HPV vaccination in the Netherlands: current evidence and future challenges in HPV-related disease prevention. <i>Expert Review of Vaccines</i> , 2018, 17, 1093-1104.	2.0	11
437	Polyvalent vaccines: High-maintenance heroes. <i>PLoS Pathogens</i> , 2018, 14, e1006904.	2.1	31
438	Genital human papillomavirus infections. <i>Frontiers in Bioscience - Landmark</i> , 2018, 23, 1587-1611.	3.0	8
439	A Tf-modified tripterine-loaded coix seed oil microemulsion enhances anti-cervical cancer treatment. <i>International Journal of Nanomedicine</i> , 2018, Volume 13, 7275-7287.	3.3	37
440	Prevalence of human papillomavirus among Wenzhou women diagnosed with cervical intraepithelial neoplasia and cervical cancer. <i>Infectious Agents and Cancer</i> , 2018, 13, 37.	1.2	12
441	N-terminal truncations on L1 proteins of human papillomaviruses promote their soluble expression in <i>Escherichia coli</i> and self-assembly in vitro. <i>Emerging Microbes and Infections</i> , 2018, 7, 1-12.	3.0	17
443	Human Papillomavirus Vaccines: Successes and Future Challenges. <i>Drugs</i> , 2018, 78, 1385-1396.	4.9	27
444	High Whole-Genome Sequence Diversity of Human Papillomavirus Type 18 Isolates. <i>Viruses</i> , 2018, 10, 68.	1.5	14
445	Human papillomaviruses other than 16, 18 and 45 are the major high risk HPV genotypes amongst women with abnormal cervical smear cytology residing in Kuwait: Implications for future vaccination strategies. <i>Diagnostic Cytopathology</i> , 2018, 46, 1036-1039.	0.5	4
446	Recent advances in the management of anal cancer. <i>F1000Research</i> , 2018, 7, 1572.	0.8	25
447	A comprehensive in silico analysis for identification of therapeutic epitopes in HPV16, 18, 31 and 45 oncoproteins. <i>PLoS ONE</i> , 2018, 13, e0205933.	1.1	25



#	ARTICLE	IF	CITATIONS
448	Persistence of immune response following bivalent HPV vaccination: A follow-up study among girls routinely vaccinated with a two-dose schedule. <i>Vaccine</i> , 2018, 36, 7580-7587.	1.7	6
449	Nanoparticles Based on Poly (l <sup>2</sup> -Amino Ester) and HPV16-Targeting CRISPR/shRNA as Potential Drugs for HPV16-Related Cervical Malignancy. <i>Molecular Therapy</i> , 2018, 26, 2443-2455.	3.7	43
450	Optimizing a Human Papillomavirus Type 16 L1-Based Chimaeric Gene for Expression in Plants. <i>Frontiers in Bioengineering and Biotechnology</i> , 2018, 6, 101.	2.0	6
451	Gynaecological disease in the developing world: a silent pandemic. <i>The Obstetrician and Gynaecologist</i> , 2018, 20, 237-244.	0.2	13
452	Strategies for screening and early detection of anal cancers: A narrative and systematic review and meta-analysis of cytology, HPV testing, and other biomarkers. <i>Cancer Cytopathology</i> , 2018, 126, 447-460.	1.4	72
453	Efficacy, Immunogenicity, and Safety of a 9-Valent Human Papillomavirus Vaccine: Subgroup Analysis of Participants From Asian Countries. <i>Journal of Infectious Diseases</i> , 2018, 218, 95-108.	1.9	29
455	Cervical Cancer Incidence in Young U.S. Females After Human Papillomavirus Vaccine Introduction. <i>American Journal of Preventive Medicine</i> , 2018, 55, 197-204.	1.6	109
456	Gender-neutral vaccination provides improved control of human papillomavirus types 18/31/33/35 through herd immunity: Results of a community randomized trial (III). <i>International Journal of Cancer</i> , 2018, 143, 2299-2310.	2.3	46
457	Prevalence and distribution of HPV genotypes and cervical-associated lesions in sexually active young French women following HPV vaccine. <i>Journal of Gynecology Obstetrics and Human Reproduction</i> , 2018, 47, 525-531.	0.6	7
458	Distribution and role of high-risk human papillomavirus genotypes in women with cervical intraepithelial neoplasia: A retrospective analysis from Wenzhou, southeast China. <i>Cancer Medicine</i> , 2018, 7, 3492-3500.	1.3	19
459	Potential impact of introducing a nonavalent HPV vaccination. <i>International Journal of Gynecology and Obstetrics</i> , 2018, 142, 338-342.	1.0	8
460	HPV single-dose vaccination: Impact potential, evidence base and further evaluation. <i>Vaccine</i> , 2018, 36, 4759-4760.	1.7	18
461	Human Papillomavirus Vaccines. , 2018, , 430-455.e10.		5
462	HPV vaccination and the effects on rates of HPV-related cancers. <i>Current Problems in Cancer</i> , 2018, 42, 493-506.	1.0	62
463	Model-estimated effectiveness of single dose 9-valent HPV vaccination for HIV-positive and HIV-negative females in South Africa. <i>Vaccine</i> , 2018, 36, 4830-4836.	1.7	27
464	Critical concepts in adaptive clinical trials. <i>Clinical Epidemiology</i> , 2018, Volume 10, 343-351.	1.5	62
465	HPV Vaccination Syndrome: A Clinical Mirage, or a New Tragic Fibromyalgia Model. <i>Reumatologia Clínica (English Edition)</i> , 2018, 14, 211-214.	0.2	3
466	Cancer immunoprevention: from mice to early clinical trials. <i>BMC Immunology</i> , 2018, 19, 16.	0.9	9

#	ARTICLE	IF	CITATIONS
467	The Diagnostic and Therapeutic Challenge of Anal Intraepithelial Neoplasia. <i>Current Gastroenterology Reports</i> , 2018, 20, 38.	1.1	2
468	Somatic mutation profiling of vulvar cancer: Exploring therapeutic targets. <i>Gynecologic Oncology</i> , 2018, 150, 552-561.	0.6	45
469	High-Risk Human Papillomaviral Oncogenes E6 and E7 Target Key Cellular Pathways to Achieve Oncogenesis. <i>International Journal of Molecular Sciences</i> , 2018, 19, 1706.	1.8	137
470	Proposal for cervical cancer screening in the era of HPV vaccination. <i>Obstetrics and Gynecology Science</i> , 2018, 61, 298.	0.6	13
471	Development of a human papillomavirus type 6/11 vaccine candidate for the prevention of condyloma acuminatum. <i>Vaccine</i> , 2018, 36, 4927-4934.	1.7	9
472	Principles and Developments in Cancer Immunotherapy and Approaches for Combination with Tumour Irradiation. <i>Progress in Tumor Research</i> , 2018, , 1-10.	0.1	0
473	Barriers, supports, and effective interventions for uptake of human papillomavirus- and other vaccines within global and Canadian Indigenous peoples: a systematic review protocol. <i>Systematic Reviews</i> , 2018, 7, 40.	2.5	12
474	Prophylactic vaccination against human papillomaviruses to prevent cervical cancer and its precursors. <i>The Cochrane Library</i> , 2020, 2020, CD009069.	1.5	288
475	Prevalence of high-risk HPV genotypes, categorised by their quadrivalent and nine-valent HPV vaccination coverage, and the genotype association with high-grade lesions. <i>BMC Cancer</i> , 2018, 18, 112.	1.1	43
476	Epidemiologic and economic burden of HPV diseases in Spain: implication of additional 5 types from the 9-valent vaccine. <i>Infectious Agents and Cancer</i> , 2018, 13, 15.	1.2	14
477	Oral human Papillomavirus DNA detection in HIV-positive men: prevalence, predictors, and co-occurrence at anal site. <i>BMC Infectious Diseases</i> , 2018, 18, 25.	1.3	18
478	Monitoring vaccine and non-vaccine HPV type prevalence in the post-vaccination era in women living in the Basilicata region, Italy. <i>BMC Infectious Diseases</i> , 2018, 18, 38.	1.3	35
479	Prevalence and genotype distribution of human papillomavirus infection among women in northeastern Guangdong Province of China. <i>BMC Infectious Diseases</i> , 2018, 18, 204.	1.3	39
480	Recommendations and barriers to vaccination in systemic lupus erythematosus. <i>Autoimmunity Reviews</i> , 2018, 17, 990-1001.	2.5	24
481	Prevalence, incidence and correlates of low risk HPV infection and anogenital warts in a cohort of women living with HIV in Burkina Faso and South Africa. <i>PLoS ONE</i> , 2018, 13, e0196018.	1.1	14
482	Bivalent Vaccine Effectiveness Against Type-Specific HPV Positivity: Evidence for Cross-Protection Against Oncogenic Types Among Dutch STI Clinic Visitors. <i>Journal of Infectious Diseases</i> , 2018, 217, 213-222.	1.9	72
483	Which human papillomavirus vaccine and vaccination strategy for national programs?. <i>Acta Obstetrica Et Gynecologica Scandinavica</i> , 2018, 97, 1049-1050.	1.3	0
484	Making <sc>HPV</sc> vaccination available to girls everywhere. <i>International Journal of Gynecology and Obstetrics</i> , 2018, 143, 267-276.	1.0	21

#	ARTICLE	IF	CITATIONS
485	Prevalence of human papillomavirus genotypes and precancerous cervical lesions in a screening population in the Republic of Korea, 2014–2016. <i>Journal of Gynecologic Oncology</i> , 2018, 29, e14.	1.0	29
486	Simultaneously characterizing the comparative economics of routine female adolescent nonavalent human papillomavirus (HPV) vaccination and assortativity of sexual mixing in Hong Kong Chinese: a modeling analysis. <i>BMC Medicine</i> , 2018, 16, 127.	2.3	14
487	Decline of HPV infections in Scandinavian cervical screening populations after introduction of HPV vaccination programs. <i>Vaccine</i> , 2018, 36, 3820-3829.	1.7	33
488	Recurrence of Genital Infections With 9 Human Papillomavirus (HPV) Vaccine Types (6, 11, 16, 18, 31, 33). <i>Tj ETQq1 1 0.784314 rgBT</i> (C), 2018, 1219-1227.	1.9	9
489	Quality Improvement Initiative to Improve Human Papillomavirus Vaccine Initiation at 9 Years of Age. <i>Academic Pediatrics</i> , 2018, 18, 769-775.	1.0	36
490	Cost-effectiveness of nonavalent HPV vaccination among males aged 22 through 26 years in the United States. <i>Vaccine</i> , 2018, 36, 4362-4368.	1.7	18
491	Nano-Pulse Stimulation induces immunogenic cell death in human papillomavirus-transformed tumors and initiates an adaptive immune response. <i>PLoS ONE</i> , 2018, 13, e0191311.	1.1	38
492	Adenovirus based HPV L2 vaccine induces broad cross-reactive humoral immune responses. <i>Vaccine</i> , 2018, 36, 4462-4470.	1.7	16
496	A National Survey of Canadian Adults on HPV: Knowledge, Attitudes, and Barriers to the HPV Vaccine. <i>Journal of Obstetrics and Gynaecology Canada</i> , 2019, 41, 1125-1133.e6.	0.3	9
497	&lt;p&gt;Recombinant human papillomavirus nonavalent vaccine in the prevention of cancers caused by human papillomavirus&lt;/p&gt;. <i>Infection and Drug Resistance</i> , 2019, Volume 12, 1951-1967.	1.1	47
498	NVN1000, a novel nitric oxide-releasing compound, inhibits HPV-18 virus production by interfering with E6 and E7 oncoprotein functions. <i>Antiviral Research</i> , 2019, 170, 104559.	1.9	12
500	Clustering patterns of type–type combination in multiple genotypes infections of human papillomavirus in cervical adenocarcinoma. <i>Journal of Medical Virology</i> , 2019, 91, 2001-2008.	2.5	8
501	Update on Diagnosis and Management of Conjunctival Papilloma. <i>Eye and Vision (London, England)</i> , 2019, 6, 18.	1.4	32
502	HPV vaccine: adverse event signals were minimised or ignored. <i>BMJ: British Medical Journal</i> , 2019, 366, l4508.	2.4	5
503	<p>Factors associated with human papillomavirus infection – findings from a cervical cancer screening program for female employees in Beijing</p>. <i>Cancer Management and Research</i> , 2019, Volume 11, 8033-8041.	0.9	3
504	Estimating incidence rates of grouped HPV types: A systematic review and comparison of the impact of different epidemiological assumptions. <i>Papillomavirus Research (Amsterdam, Netherlands)</i> , 2019, 8, 100187.	4.5	4
505	An observational study comparing HPV prevalence and type distribution between HPV-vaccinated and -unvaccinated girls after introduction of school-based HPV vaccination in Norway. <i>PLoS ONE</i> , 2019, 14, e0223612.	1.1	13
506	Recent advances in nanotheranostics for triple negative breast cancer treatment. <i>Journal of Experimental and Clinical Cancer Research</i> , 2019, 38, 430.	3.5	121

#	ARTICLE	IF	CITATIONS
507	Reduction in HPV16/18 prevalence among young women with high-grade cervical lesions following the Japanese HPV vaccination program. <i>Cancer Science</i> , 2019, 110, 3811-3820.	1.7	26
508	Prophylactic vaccination against human papillomaviruses to prevent vulval and vaginal cancer and their precursors. <i>Expert Review of Vaccines</i> , 2019, 18, 1157-1166.	2.0	21
509	Contemporary Issues in Women's Health. <i>International Journal of Gynecology and Obstetrics</i> , 2019, 147, 1-3.	1.0	1
510	Human Oncogenic Viruses: Old Facts and New Hypotheses. <i>Molecular Biology</i> , 2019, 53, 767-775.	0.4	5
511	Untangling the dynamics of persistence and colonization in microbial communities. <i>ISME Journal</i> , 2019, 13, 2998-3010.	4.4	3
512	Profile of MeltPro® HPV test for human papillomavirus genotyping and cervical precancer screening. <i>Expert Review of Molecular Diagnostics</i> , 2019, 19, 857-862.	1.5	3
513	Exploration of the effect of human papillomavirus (HPV) vaccination in a cohort of pregnant women in Montreal, 2010-2016. <i>Heliyon</i> , 2019, 5, e02150.	1.4	10
514	Viral metagenomics updated the prevalence of human papillomavirus types in anogenital warts. <i>Emerging Microbes and Infections</i> , 2019, 8, 1291-1299.	3.0	9
515	Dynamic factors affecting HPV-attributable fraction for head and neck cancers. <i>Current Opinion in Virology</i> , 2019, 39, 33-40.	2.6	21
516	Safety and efficacy of human papillomavirus vaccination for people living with HIV: A systematic review and meta-analysis. <i>International Journal of STD and AIDS</i> , 2019, 30, 1105-1115.	0.5	12
517	A systematic approach to map the adolescent human papillomavirus vaccine decision and identify intervention strategies to address vaccine hesitancy. <i>Public Health</i> , 2019, 177, 71-79.	1.4	11
518	Positivity and prevalence of human papillomavirus among a large population of women in southeastern China. <i>Journal of International Medical Research</i> , 2019, 47, 6171-6181.	0.4	5
519	Long-term HPV-specific immune response after one versus two and three doses of bivalent HPV vaccination in Dutch girls. <i>Vaccine</i> , 2019, 37, 7280-7288.	1.7	14
520	Human papillomavirus (HPV) vaccination: from clinical studies to immunization programs. <i>International Journal of Gynecological Cancer</i> , 2019, 29, 1317-1326.	1.2	11
521	Diversity of human papillomavirus typing among women population living in rural and remote areas of Brazilian territory. <i>Papillomavirus Research (Amsterdam, Netherlands)</i> , 2019, 8, 100186.	4.5	5
522	Human Papillomavirus Vaccination Coverage Gaps in Young Adolescents. <i>Journal of Infectious Diseases</i> , 2019, 220, 727-729.	1.9	2
523	Eradication of human papillomavirus and elimination of HPV-related diseases – scientific basis for global public health policies. <i>Expert Review of Vaccines</i> , 2019, 18, 153-160.	2.0	41
524	Estimating the epidemiological impact and cost-effectiveness profile of a nonavalent HPV vaccine in Spain. <i>Human Vaccines and Immunotherapeutics</i> , 2019, 15, 1949-1961.	1.4	19

#	ARTICLE	IF	CITATIONS
525	Prevalence of high-risk human papilloma virus in women with high-grade squamous cell intraepithelial lesions in Botswana using Abbott RealTime HPV assay. <i>PLoS ONE</i> , 2019, 14, e0211260.	1.1	10
527	Human Papillomavirus Vaccine Effectiveness and Herd Protection in Young Women. <i>Pediatrics</i> , 2019, 143, .	1.0	45
528	(At Least) Once in Her Lifetime: Global Cervical Cancer Prevention. <i>Obstetrics and Gynecology Clinics of North America</i> , 2019, 46, 107-123.	0.7	12
530	Physician clinical decision support system prompts and administration of subsequent doses of HPV vaccine: A randomized clinical trial. <i>Vaccine</i> , 2019, 37, 4414-4418.	1.7	16
532	Age-specific HPV type distribution in high-grade cervical disease in screened and unvaccinated women. <i>Gynecologic Oncology</i> , 2019, 154, 354-359.	0.6	36
533	Incorporation of RG1 epitope into HPV16L1-VLP does not compromise L1-specific immunity. <i>Vaccine</i> , 2019, 37, 3529-3534.	1.7	13
534	Disorders of the Colon and Rectum. <i>Clinical Gastroenterology</i> , 2019, , 173-192.	0.0	1
535	High prevalence of cervical high-risk human papillomavirus infection mostly covered by Gardasil-9 prophylactic vaccine in adult women living in Nâ€™Djamena, Chad. <i>PLoS ONE</i> , 2019, 14, e0217486.	1.1	17
536	A significant portion of college students are not aware of HPV disease and HPV vaccine recommendations. <i>Human Vaccines and Immunotherapeutics</i> , 2019, 15, 1760-1766.	1.4	49
537	Natural history, dynamics, and ecology of human papillomaviruses in genital infections of young women: protocol of the PAPCLEAR cohort study. <i>BMJ Open</i> , 2019, 9, e025129.	0.8	17
538	An effective and biocompatible polyethylenimine based vaginal suppository for gene delivery. <i>Nanomedicine: Nanotechnology, Biology, and Medicine</i> , 2019, 20, 101994.	1.7	11
539	Prevalence and distribution of HPV types in genital warts in Xiâ€™an, China: a prospective study. <i>BMJ Open</i> , 2019, 9, e023897.	0.8	23
540	Update on HPV Vaccination. , 2019, , 443-450.		0
541	Should female sex workers be offered HPV vaccination?. <i>Human Vaccines and Immunotherapeutics</i> , 2019, 15, 1544-1548.	1.4	12
543	<sc>HPV</sc>â€™vaccination and cancer cervical screening in 53 <sc>WHO</sc> European Countries: An update on prevention programs according to income level. <i>Cancer Medicine</i> , 2019, 8, 2524-2534.	1.3	32
545	Immune Checkpoint Blockade in PD-L1â€™Positive Platinum-Refractory Cervical Carcinoma. <i>Journal of Clinical Oncology</i> , 2019, 37, 1449-1454.	0.8	8
546	Prevalence and genotypes of anal human papillomavirus infection among HIV-positive<i>vs</i>. HIV-negative men in Taizhou, China. <i>Epidemiology and Infection</i> , 2019, 147, e117.	1.0	19
547	Effect of the bivalent HPV vaccine on viral load of vaccine and non-vaccine HPV types in incident clearing and persistent infections in young Dutch females. <i>PLoS ONE</i> , 2019, 14, e0212927.	1.1	15

#	ARTICLE	IF	CITATIONS
548	Clinical guideline for 9-valent HPV vaccine: Korean Society of Gynecologic Oncology Guideline. Journal of Gynecologic Oncology, 2019, 30, e31.	1.0	6
549	Effect of vaccination against oral HPV-16 infection in high school students in the city of Cali, Colombia. Papillomavirus Research (Amsterdam, Netherlands), 2019, 7, 112-117.	4.5	14
550	“We are Muslims and these diseases don’t happen to us”: A qualitative study of the views of young Somali men and women concerning HPV immunization. Vaccine, 2019, 37, 2043-2050.	1.7	17
551	Hispanic Mothers’ Beliefs About Having Their Adolescent Sons Initiate the HPV Vaccine Series. Journal of Immigrant and Minority Health, 2019, 21, 1356-1364.	0.8	6
552	HPV Vaccine: Updates and Highlights. Acta Cytologica, 2019, 63, 159-168.	0.7	53
553	Vulvar Disease. , 2019, , .		4
555	Nine-valent HPV vaccine efficacy against related diseases and definitive therapy: comparison with historic placebo population. Gynecologic Oncology, 2019, 154, 110-117.	0.6	62
556	The effectiveness of vaccination to prevent the papillomavirus infection: a systematic review and meta-analysis. Epidemiology and Infection, 2019, 147, e156.	1.0	6
557	Genital Condyloma (HPV Infection). , 2019, , 107-117.		0
558	Anal Squamous Intraepithelial Neoplasia. , 2019, , 379-383.		0
559	Durability of the neutralizing antibody response to vaccine and non-vaccine HPV types 7 years following immunization with either Cervarix® or Gardasil® vaccine. Vaccine, 2019, 37, 2455-2462.	1.7	26
560	Strength of belief: Religious commitment, knowledge, and HPV vaccination adherence. Psycho-Oncology, 2019, 28, 1227-1233.	1.0	15
561	Gynecological Cancers—the Changing Paradigm. Indian Journal of Surgical Oncology, 2019, 10, 156-161.	0.3	0
562	Toward a Model of HPV Vaccine Series Completion in Adolescent Hispanic Males. Family and Community Health, 2019, 42, 161-169.	0.5	10
563	Occurrence of human papillomavirus (HPV) type replacement by sexual risk-taking behaviour group: Post-hoc analysis of a community randomized clinical trial up to nine years after vaccination (IV). International Journal of Cancer, 2019, 145, 785-796.	2.3	20
564	A mobile-phone based high-resolution microendoscope to image cervical precancer. PLoS ONE, 2019, 14, e0211045.	1.1	13
565	Post-hoc analysis from phase III trials of human papillomavirus vaccines: considerations on impact on non-vaccine types. Expert Review of Vaccines, 2019, 18, 309-322.	2.0	15
566	Nanoparticle systems for cancer vaccine. Nanomedicine, 2019, 14, 627-648.	1.7	85

#	ARTICLE	IF	CITATIONS
567	Peptide Super-Agonist Enhances T-Cell Responses to Melanoma. <i>Frontiers in Immunology</i> , 2019, 10, 319.	2.2	18
568	â™€Intraepithelial Lesions of the Vulva. , 2019, , 346-353.		0
569	Current status of human papillomavirus vaccination in India's cervical cancer prevention efforts. <i>Lancet Oncology</i> , The, 2019, 20, e637-e644.	5.1	76
570	How I treat anal squamous cell carcinoma. <i>ESMO Open</i> , 2019, 4, e000711.	2.0	4
571	Near Real-Time Surveillance to Assess the Safety of the 9-Valent Human Papillomavirus Vaccine. <i>Pediatrics</i> , 2019, 144, .	1.0	30
572	Adverse events associated with human papillomavirus vaccines: a protocol for systematic review with network meta-analysis incorporating all randomised controlled trials comparing with placebo, adjuvants and other vaccines. <i>BMJ Open</i> , 2019, 9, e026924.	0.8	1
573	Text and Email Messaging for Increasing Human Papillomavirus Vaccine Completion among Uninsured or Medicaid-insured Adolescents in Rural Eastern North Carolina. <i>Journal of Health Care for the Poor and Underserved</i> , 2019, 30, 1499-1517.	0.4	14
574	Vaccination of Young Women Decreases Human Papillomavirus Transmission in Heterosexual Couples: Findings from the HITCH Cohort Study. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2019, 28, 1825-1834.	1.1	13
577	Age-Related Changes in the Fraction of Cervical Intraepithelial Neoplasia Grade 3 Related to HPV Genotypes Included in the Nonavalent Vaccine. <i>Journal of Oncology</i> , 2019, 2019, 1-7.	0.6	11
578	Comparison of different human papillomavirus (HPV) vaccine types and dose schedules for prevention of HPV-related disease in females and males. <i>The Cochrane Library</i> , 2019, 2019, .	1.5	65
579	HPV infection and the genital cytokine milieu in women at high risk of HIV acquisition. <i>Nature Communications</i> , 2019, 10, 5227.	5.8	40
581	Long-term Immunogenicity and Safety of the AS04-adjuvanted Human Papillomavirusâ€™16/18 Vaccine in Four- to Six-year-old Girls. <i>Pediatric Infectious Disease Journal</i> , 2019, 38, 1061-1067.	1.1	11
582	Tablet-Based Patient Education Regarding Human Papillomavirus Vaccination in Colposcopy Clinic. <i>Journal of Lower Genital Tract Disease</i> , 2019, 23, 188-192.	0.9	7
583	HPV-associated cancers. <i>Memo - Magazine of European Medical Oncology</i> , 2019, 12, 352-356.	0.3	0
584	Estimating the Human Papillomavirus Genotype Attribution in Screen-detected High-grade Cervical Lesions. <i>Epidemiology</i> , 2019, 30, 590-596.	1.2	9
585	Human Papillomavirus Vaccination and Anogenital Warts: A Systematic Review of Impact and Effectiveness in the United States. <i>Sexually Transmitted Diseases</i> , 2019, 46, 213-220.	0.8	20
586	Clinical Controversies in Cervical Cancer Screening. <i>Clinical Obstetrics and Gynecology</i> , 2019, 62, 644-655.	0.6	2
587	Prevalence of HPV among HIV-negative women of child-bearing age in LomÃ©, Togo. <i>Future Virology</i> , 2019, 14, 783-790.	0.9	1

#	ARTICLE	IF	CITATIONS
588	Safety of the 9-Valent Human Papillomavirus Vaccine. <i>Pediatrics</i> , 2019, 144, .	1.0	39
589	Human papillomavirus and p16 in squamous cell carcinoma and intraepithelial neoplasia of the vagina. <i>International Journal of Cancer</i> , 2019, 145, 78-86.	2.3	41
590	HPV-Associated Anal Cancer in the HIV/AIDS Patient. <i>Cancer Treatment and Research</i> , 2019, 177, 183-209.	0.2	41
591	The Role of Human Papilloma Virus in Penile Cancer Prevention and New Therapeutic Agents. <i>European Urology Focus</i> , 2019, 5, 42-45.	1.6	20
592	HPV prevalence and genotype distribution among women in Shandong Province, China: Analysis of 94,489 HPV genotyping results from Shandong's largest independent pathology laboratory. <i>PLoS ONE</i> , 2019, 14, e0210311.	1.1	47
593	Uterine Cervical Cancer. , 2019, , .		3
594	A Very Common Intimate Concern: "Will My Genital Warts Ever Stop Recurring?" <i>Journal of Infectious Diseases</i> , 2019, 219, 682-684.	1.9	0
595	Human papillomavirus types causing recurrent respiratory papillomatosis in Zimbabwe. <i>International Journal of Pediatric Otorhinolaryngology</i> , 2019, 116, 147-152.	0.4	4
596	Therapeutic Use of the Human Papillomavirus Vaccine on Recurrent Respiratory Papillomatosis: A Systematic Review and Meta-Analysis. <i>Journal of Infectious Diseases</i> , 2019, 219, 1016-1025.	1.9	51
597	New prophylactics human papilloma virus (HPV) vaccines against cervical cancer. <i>Journal of Obstetrics and Gynaecology</i> , 2019, 39, 1-10.	0.4	41
598	Investigating the aetiology of adverse events following HPV vaccination with systems vaccinology. <i>Cellular and Molecular Life Sciences</i> , 2019, 76, 67-87.	2.4	6
599	Human Papillomavirus Prevalence Among American Indian Women of the Great Plains. <i>Journal of Infectious Diseases</i> , 2019, 219, 908-915.	1.9	10
600	The 5th virus-like particle and nano-particle vaccines (VLPNPV) conference. <i>Expert Review of Vaccines</i> , 2019, 18, 1-3.	2.0	6
601	Genomic Applications in Head and Neck Cancers. , 2019, , 309-324.		0
602	HIV/AIDS-Associated Viral Oncogenesis. <i>Cancer Treatment and Research</i> , 2019, , .	0.2	0
603	Detection of human papillomavirus 67 single infection in high-grade cervical lesions: Case report and review of literature. <i>Diagnostic Cytopathology</i> , 2019, 47, 251-254.	0.5	1
604	Achieving high HPV vaccine completion rates in a pediatric clinic population. <i>Human Vaccines and Immunotherapeutics</i> , 2019, 15, 1562-1569.	1.4	21
605	Incident genital HPV infections and potential impact of HPV vaccines in adult women living with HIV/AIDS. <i>Human Vaccines and Immunotherapeutics</i> , 2019, 15, 1904-1910.	1.4	3



#	ARTICLE	IF	CITATIONS
606	Maternal transfer of anti HPV 6 and 11 antibodies upon immunization with the 9-valent HPV vaccine. <i>Human Vaccines and Immunotherapeutics</i> , 2019, 15, 141-145.	1.4	5
607	Identifying Hispanic mothers' salient beliefs about human papillomavirus vaccine initiation in their adolescent daughters. <i>Journal of Health Psychology</i> , 2019, 24, 453-465.	1.3	3
608	Efficacy, Safety, and Immunogenicity of an Escherichia coli-Produced Bivalent Human Papillomavirus Vaccine: An Interim Analysis of a Randomized Clinical Trial. <i>Journal of the National Cancer Institute</i> , 2020, 112, 145-153.	3.0	99
609	Immunogenicity noninferiority study of 2 doses and 3 doses of an Escherichia coli-produced HPV bivalent vaccine in girls vs. 3 doses in young women. <i>Science China Life Sciences</i> , 2020, 63, 582-591.	2.3	34
610	Lifestyle and Cancer Prevention. , 2020, , 337-374.e12.		3
611	Knowledge, practice and attitude towards HPV vaccination among college students in Beijing, China. <i>Human Vaccines and Immunotherapeutics</i> , 2020, 16, 116-123.	1.4	39
612	A systematic review of immunogenicity, clinical efficacy and safety of human papillomavirus vaccines in people living with the human immunodeficiency virus. <i>Human Vaccines and Immunotherapeutics</i> , 2020, 16, 426-435.	1.4	7
613	Pregnancy Outcomes After Human Papillomavirus Vaccination in Periconceptional Period or During Pregnancy: A Systematic Review and Meta-analysis. <i>Human Vaccines and Immunotherapeutics</i> , 2020, 16, 581-589.	1.4	10
614	Regulation of Mucosal Immunity in the Genital Tract: Balancing Reproduction and Protective Immunity. , 2020, , 255-297.		2
615	Development of HPV16,18,31,45 E5 and E7 peptides-based vaccines predicted by immunoinformatics tools. <i>Biotechnology Letters</i> , 2020, 42, 403-418.	1.1	27
616	Persisting Antibody Response 9 Years After Bivalent Human Papillomavirus (HPV) Vaccination in a Cohort of Dutch Women: Immune Response and the Relation to Genital HPV Infections. <i>Journal of Infectious Diseases</i> , 2020, 221, 1884-1894.	1.9	8
617	Difference Between Medical and Nonmedical Students on Knowledge, Practice, and Attitude Towards the Human Papillomavirus Vaccine in China: a Cross-Sectional Study. <i>Journal of Cancer Education</i> , 2020, 36, 1014-1021.	0.6	3
618	Human papillomavirus vaccine against cervical cancer: Opportunity and challenge. <i>Cancer Letters</i> , 2020, 471, 88-102.	3.2	229
619	Oropharyngeal Human Papillomavirus and Head and Neck Cancer. , 2020, , 205-217.		0
620	Clinical Trials of Human Papillomavirus Vaccines. , 2020, , 299-325.		1
621	The Key Role of Mathematical Modeling and Health Economics in the Public Health Transitions in Cervical Cancer Prevention. , 2020, , 333-347.		0
622	Estimates of incidence and mortality of cervical cancer in 2018: a worldwide analysis. <i>The Lancet Global Health</i> , 2020, 8, e191-e203.	2.9	2,111
623	Baseline findings and safety of infrequent vs frequent screening of human papillomavirus vaccinated women. <i>International Journal of Cancer</i> , 2020, 147, 440-447.	2.3	8

#	ARTICLE	IF	CITATIONS
624	Different types of adjuvants in prophylactic and therapeutic human papillomavirus vaccines in laboratory animals: a systematic review. <i>Archives of Virology</i> , 2020, 165, 263-284.	0.9	13
625	Temporal Trends in the Incidence of Anogenital Warts: Impact of Human Papillomavirus Vaccination. <i>Sexually Transmitted Diseases</i> , 2020, 47, 179-186.	0.8	2
626	A Virus-Infected, Reprogrammed Somatic Cell-Derived Tumor Cell (VIREST) Vaccination Regime Can Prevent Initiation and Progression of Pancreatic Cancer. <i>Clinical Cancer Research</i> , 2020, 26, 465-476.	3.2	24
627	Virus-like Particle-Based L2 Vaccines against HPVs: Where Are We Today?. <i>Viruses</i> , 2020, 12, 18.	1.5	37
628	Efficacy and immunogenicity of a single dose of human papillomavirus vaccine compared to no vaccination or standard three and two-dose vaccination regimens: A systematic review of evidence from clinical trials. <i>Vaccine</i> , 2020, 38, 1302-1314.	1.7	61
629	Treatment Combinations with DNA Vaccines for the Treatment of Metastatic Castration-Resistant Prostate Cancer (mCRPC). <i>Cancers</i> , 2020, 12, 2831.	1.7	12
630	Occupational Exposure to Human Papillomavirus and Vaccination for Health Care Workers. <i>Obstetrics and Gynecology</i> , 2020, 136, 663-665.	1.2	8
631	Cervical Cancer Incidence and Mortality among Non-Hispanic African American and White Women, United States, 1999-2015. <i>Journal of the National Medical Association</i> , 2020, 112, 632-638.	0.6	7
632	Post-hoc analysis of injection-site reactions following vaccination with quadrivalent human papillomavirus vaccine in Japanese female clinical trial participants. <i>Papillomavirus Research (Amsterdam, Netherlands)</i> , 2020, 10, 100205.	4.5	2
633	From the Infection to the Immunotherapy in Cervical Cancer: Can We Stop the Natural Course of the Disease?. <i>Vaccines</i> , 2020, 8, 597.	2.1	8
634	HPVomics: An integrated resource for the human papillomavirus epitome and therapeutics. <i>Genomics</i> , 2020, 112, 4853-4862.	1.3	1
635	Prevalence of human papillomavirus genotypes and precancerous cervical lesions in a screening population in Beijing, China: analysis of results from China's top 3 hospital, 2009-2019. <i>Virology Journal</i> , 2020, 17, 104.	1.4	14
636	Gulf war illness, post-HPV vaccination syndrome, and Macrophagic Myofasciitis. Similar disabling conditions possibly linked to vaccine-induced autoimmune dysautonomia.. <i>Autoimmunity Reviews</i> , 2020, 19, 102603.	2.5	5
637	Long-term immunogenicity, effectiveness, and safety of nine-valent human papillomavirus vaccine in girls and boys 9 to 15 years of age: Interim analysis after 8 years of follow-up. <i>Papillomavirus Research (Amsterdam, Netherlands)</i> , 2020, 10, 100203.	4.5	34
638	Induction of cross-neutralizing antibodies by sequential immunization with heterologous papillomavirus L1VLPs and its implications for HPV prophylactic vaccines. <i>Journal of Medical Virology</i> , 2020, 92, 3750-3758.	2.5	4
639	Cost-effectiveness of HPV vaccination for adults through age 45 years in the United States: Estimates from a simplified transmission model. <i>Vaccine</i> , 2020, 38, 8032-8039.	1.7	17
640	Efficacy of the bivalent HPV vaccine against HPV 16/18-associated precancer: long-term follow-up results from the Costa Rica Vaccine Trial. <i>Lancet Oncology</i> , The, 2020, 21, 1643-1652.	5.1	54
641	Human Papillomavirus Immunization and the Elimination of Cervical Carcinoma. <i>Annals of Internal Medicine</i> , 2020, 173, 935-936.	2.0	1

#	ARTICLE	IF	CITATIONS
642	Human Papillomavirus Infection Rates before and after the Introduction of Prophylactic Vaccines in Kunming, Yunnan, China. <i>Indian Journal of Medical Microbiology</i> , 2020, 38, 66-71.	0.3	1
643	Human Papillomavirus Vaccines: An Updated Review. <i>Vaccines</i> , 2020, 8, 391.	2.1	130
644	Cervical Dysplasia, Infection, and Phylogeny of Human Papillomavirus in HIV-Infected and HIV-Uninfected Women at a Reproductive Health Clinic in Nairobi, Kenya. <i>BioMed Research International</i> , 2020, 2020, 1-10.	0.9	8
645	Progress in Vaccination of Prophylactic Human Papillomavirus Vaccine. <i>Frontiers in Immunology</i> , 2020, 11, 1434.	2.2	15
646	Comparing immunogenicity of the Escherichia coli-produced bivalent human papillomavirus vaccine in females of different ages. <i>Vaccine</i> , 2020, 38, 6096-6102.	1.7	9
647	Epidemiologic Profile of Type-Specific Human Papillomavirus Infection after Initiation of HPV Vaccination. <i>Vaccines</i> , 2020, 8, 425.	2.1	8
648	Long-term persistence of immune response to the AS04-adjuvanted HPV16/18 vaccine in Chinese girls aged 9-17 years: Results from an 8-year follow-up phase III open-label study. <i>Asia-Pacific Journal of Clinical Oncology</i> , 2020, 16, 392-399.	0.7	2
649	Transmission reduction and prevention with HPV vaccination (TRAP-HPV) study protocol: a randomised controlled trial of the efficacy of HPV vaccination in preventing transmission of HPV infection in heterosexual couples. <i>BMJ Open</i> , 2020, 10, e039383.	0.8	6
650	Plant-Derived Natural Compounds in Genetic Vaccination and Therapy for HPV-Associated Cancers. <i>Cancers</i> , 2020, 12, 3101.	1.7	14
651	Immunogenicity of Alternative Dosing Schedules for HPV Vaccines among Adolescent Girls and Young Women: A Systematic Review and Meta-Analysis. <i>Vaccines</i> , 2020, 8, 618.	2.1	4
652	Prevalence and genotype distribution of cervical human papillomavirus infection in the pre-vaccination era: a population-based study in the Canary Islands. <i>BMJ Open</i> , 2020, 10, e037402.	0.8	7
653	Human Papillomavirus, Herpes Zoster, and Hepatitis B Vaccinations in Immunocompromised Patients: An Update for Pharmacists. <i>Journal of Pharmacy Practice</i> , 2020, 34, 089719002095826.	0.5	1
654	Oligometastasis: Past, Present, Future. <i>International Journal of Radiation Oncology Biology Physics</i> , 2020, 108, 530-538.	0.4	27
655	Knowledge of the Human Papillomavirus by Social Stratification Factors. <i>Nursing Research</i> , 2020, 69, E18-E25.	0.8	8
656	Antiviral therapy for the sexually transmitted viruses: recent updates on vaccine development. <i>Expert Review of Clinical Pharmacology</i> , 2020, 13, 1001-1046.	1.3	7
657	Caught in the Crossfire: How Contradictory Information and Norms on Social Media Influence Young Women's Intentions to Receive HPV Vaccination in the United States and China. <i>Frontiers in Psychology</i> , 2020, 11, 548365.	1.1	15
658	Primary Care Guidance for Persons With Human Immunodeficiency Virus: 2020 Update by the HIV Medicine Association of the Infectious Diseases Society of America. <i>Clinical Infectious Diseases</i> , 2021, 73, e3572-e3605.	2.9	123
659	Cervical and oral human papillomavirus infection in women living with human immunodeficiency virus (HIV) and matched HIV-negative controls in Brazil. <i>Infectious Agents and Cancer</i> , 2020, 15, 31.	1.2	5

#	ARTICLE	IF	CITATIONS
660	Lubricant Investigation in Men to Inhibit Transmission of HPV Infection (LIMIT-HPV): design and methods for a randomised controlled trial. <i>BMJ Open</i> , 2020, 10, e035113.	0.8	5
661	Assessing the epidemiological impact on cervical cancer of switching from 4-valent to 9-valent HPV vaccine within a gender-neutral vaccination programme in Switzerland. <i>BMC Public Health</i> , 2020, 20, 671.	1.2	8
662	Head and Neck Cancer. <i>New England Journal of Medicine</i> , 2020, 382, e57.	13.9	14
663	Incidence of vulvar high-grade precancerous lesions and cancer in Denmark before and after introduction of HPV vaccination. <i>Gynecologic Oncology</i> , 2020, 157, 664-670.	0.6	17
664	Prevalence of high-risk human papillomavirus after HPV vaccination in Denmark. <i>International Journal of Cancer</i> , 2020, 147, 3446-3452.	2.3	7
665	Immunogenicity of an Escherichia coli-produced bivalent human papillomavirus vaccine under different vaccination intervals. <i>Human Vaccines and Immunotherapeutics</i> , 2020, 16, 1630-1635.	1.4	2
666	Vaccination With Moderate Coverage Eradicates Oncogenic Human Papillomaviruses If a Gender-Neutral Strategy Is Applied. <i>Journal of Infectious Diseases</i> , 2020, 222, 948-956.	1.9	29
667	HPV vaccination and cancer prevention. <i>Best Practice and Research in Clinical Obstetrics and Gynaecology</i> , 2020, 65, 109-124.	1.4	51
668	The Use of Both Therapeutic and Prophylactic Vaccines in the Therapy of Papillomavirus Disease. <i>Frontiers in Immunology</i> , 2020, 11, 188.	2.2	93
669	Virus Like Particles (VLP) as multivalent vaccine candidate against Chikungunya, Japanese Encephalitis, Yellow Fever and Zika Virus. <i>Scientific Reports</i> , 2020, 10, 4017.	1.6	60
670	Cost-effectiveness analysis of a gender-neutral human papillomavirus vaccination program in the Netherlands. <i>Vaccine</i> , 2020, 38, 4687-4694.	1.7	12
671	Protecting people with multiple sclerosis through vaccination. <i>Practical Neurology</i> , 2020, 20, 435.1-445.	0.5	40
672	HPV Vaccination: The Position Paper of the Italian Society of Colposcopy and Cervico-Vaginal Pathology (SICPCV). <i>Vaccines</i> , 2020, 8, 354.	2.1	21
673	Immune Response Following Quadrivalent Human Papillomavirus Vaccination in Women After Hematopoietic Allogeneic Stem Cell Transplant. <i>JAMA Oncology</i> , 2020, 6, 696.	3.4	18
674	Prevalence of Sexually Transmitted Infections and Risk Factors Among Young People in a Public Health Center in Brazil: A Cross-Sectional Study. <i>Journal of Pediatric and Adolescent Gynecology</i> , 2020, 33, 354-362.	0.3	13
675	The impact of p16ink4a positivity in invasive vulvar cancer on disease-free and disease-specific survival, a retrospective study. <i>Archives of Gynecology and Obstetrics</i> , 2020, 301, 753-759.	0.8	4
676	Human Papillomavirus Genotype Replacement: Still Too Early to Tell?. <i>Journal of Infectious Diseases</i> , 2020, 224, 481-491.	1.9	25
677	<p><miR-145-5p Regulates the Proliferation, Migration and Invasion in Cervical Carcinoma by Targeting KLF5</p>. <i>OncoTargets and Therapy</i> , 2020, Volume 13, 2369-2376.	1.0	13

#	ARTICLE	IF	CITATIONS
678	A vaccine-based nanosystem for initiating innate immunity and improving tumor immunotherapy. <i>Nature Communications</i> , 2020, 11, 1985.	5.8	55
679	Burden of HPV related anogenital diseases in young women in Germany – an analysis of German statutory health insurance claims data from 2012 to 2017. <i>BMC Infectious Diseases</i> , 2020, 20, 297.	1.3	13
680	Alternative New Mono-scaled Quantitative Benefit–Risk Assessment of Human Papillomavirus Vaccine in Japan. <i>Therapeutic Innovation and Regulatory Science</i> , 2021, 55, 48-55.	0.8	0
681	How to recover lost vaccine acceptance? A multi-center survey on HPV vaccine acceptance in Japan. <i>Journal of Infection and Chemotherapy</i> , 2021, 27, 445-449.	0.8	15
682	Choosing the optimal HPV vaccine: The health impact and economic value of the nonavalent and bivalent HPV vaccines in 48 Gavi-eligible countries. <i>International Journal of Cancer</i> , 2021, 148, 932-940.	2.3	18
683	Estimating the direct effect of human papillomavirus vaccination on the lifetime risk of screen-detected cervical precancer. <i>International Journal of Cancer</i> , 2021, 148, 320-328.	2.3	7
684	Effect of an educational intervention on human papillomavirus (HPV) knowledge and attitudes towards HPV vaccines among healthcare workers (HCWs) in Western China. <i>Human Vaccines and Immunotherapeutics</i> , 2021, 17, 443-450.	1.4	16
685	Reductio ad absurdum in critical care trials. <i>Journal of Critical Care</i> , 2021, 61, 71-72.	1.0	0
686	Public health impact and cost-effectiveness of a nine-valent gender-neutral HPV vaccination program in France. <i>Vaccine</i> , 2021, 39, 438-446.	1.7	16
687	Incidence of anogenital warts: epidemiological risk factors and real-life impact of human papillomavirus vaccination. <i>International Journal of STD and AIDS</i> , 2021, 32, 4-13.	0.5	14
688	Modeling the epidemiological impact and cost-effectiveness of a combined schoolgirl HPV vaccination and cervical cancer screening program among Chinese women. <i>Human Vaccines and Immunotherapeutics</i> , 2021, 17, 1073-1082.	1.4	7
689	Long-term effectiveness of the nine-valent human papillomavirus vaccine in Scandinavian women: interim analysis after 8 years of follow-up. <i>Human Vaccines and Immunotherapeutics</i> , 2021, 17, 943-949.	1.4	24
690	Splicing Genomics Events in Cervical Cancer: Insights for Phenotypic Stratification and Biomarker Potency. <i>Genes</i> , 2021, 12, 130.	1.0	13
691	Human Papillomavirus (HPV) Vaccines and Their Impact. , 2021, , 295-299.		0
692	EMA’s mishandling of an investigation into suspected serious neurological harms of HPV vaccines. <i>BMJ Evidence-Based Medicine</i> , 2022, 27, 7-10.	1.7	3
693	Epidemiology and Burden of Human Papillomavirus and Related Diseases, Molecular Pathogenesis, and Vaccine Evaluation. <i>Frontiers in Public Health</i> , 2020, 8, 552028.	1.3	193
694	Human Papilloma Virus, its Vaccine Significance, Side Effects, and Complications. <i>Pharmacophore</i> , 2021, 12, 36-40.	0.2	0
695	Cervical Cancer Screening. , 2021, , 151-159.		0

#	ARTICLE	IF	CITATIONS
697	Public health impact and cost-effectiveness of catch-up 9-valent HPV vaccination of individuals through age 45 years in the United States. <i>Human Vaccines and Immunotherapeutics</i> , 2021, 17, 1943-1951.	1.4	24
698	Distribution of Human Papillomavirus (HPV) Genotypes in HIV-Negative and HIV-Positive Women with Cervical Intraepithelial Lesions in the Eastern Cape Province, South Africa. <i>Viruses</i> , 2021, 13, 280.	1.5	15
699	Type-specific persistence, clearance and incidence of high-risk HPV among screen-positive Rwandan women living with HIV. <i>Infectious Agents and Cancer</i> , 2021, 16, 16.	1.2	5
701	Personal Neoantigen Vaccines for the Treatment of Cancer. <i>Annual Review of Cancer Biology</i> , 2021, 5, 259-276.	2.3	13
702	Knowledge of Chinese dentists on HPV, their willingness and barriers to recommend HPV vaccination to patients. <i>Human Vaccines and Immunotherapeutics</i> , 2021, 17, 2728-2735.	1.4	1
703	Effectiveness of a universal vaccination program with an HPV quadrivalent vaccine in young Brazilian women. <i>Vaccine</i> , 2021, 39, 1840-1845.	1.7	10
704	Current and future vaccine clinical research with the licensed 2-, 4-, and 9-valent VLP HPV vaccines: What's ongoing, what's needed?. <i>Preventive Medicine</i> , 2021, 144, 106321.	1.6	12
705	Impact and cost-effectiveness of strategies to accelerate cervical cancer elimination: A model-based analysis. <i>Preventive Medicine</i> , 2021, 144, 106276.	1.6	18
706	Characteristics of human papillomavirus infection among women with cervical cytological abnormalities in the Zhoupu District, Shanghai City, China, 2014-2019. <i>Virology Journal</i> , 2021, 18, 51.	1.4	3
707	Optimal treatment in locally advanced cervical cancer. <i>Expert Review of Anticancer Therapy</i> , 2021, 21, 657-671.	1.1	23
708	The Development of Human Papillomavirus (HPV) Vaccines and Current Barriers to Implementation. <i>Immunological Investigations</i> , 2021, 50, 821-832.	1.0	5
709	Human papillomavirus vaccination for adults aged 30 to 45 years in the United States: A cost-effectiveness analysis. <i>PLoS Medicine</i> , 2021, 18, e1003534.	3.9	30
710	Catch-up HPV Vaccination and Subsequent Uptake of Papanicolaou Testing in A State-mandated Health System. <i>Cancer Prevention Research</i> , 2021, 14, 415-420.	0.7	1
711	Systematic literature review of neutralizing antibody immune responses to non-vaccine targeted high-risk HPV types induced by the bivalent and the quadrivalent vaccines. <i>Vaccine</i> , 2021, 39, 2214-2223.	1.7	7
712	Cervical Cancer Immunotherapy: Facts and Hopes. <i>Clinical Cancer Research</i> , 2021, 27, 4953-4973.	3.2	129
713	Immunogenicity and safety of a nine-valent human papillomavirus vaccine in Vietnamese males and females (9 to 26 years of age): an open-label, phase 3 trial. <i>Human Vaccines and Immunotherapeutics</i> , 2021, 17, 1980-1985.	1.4	2
714	High-risk HPV-positive and -negative high-grade cervical dysplasia: Analysis of 5-year outcomes. <i>Gynecologic Oncology</i> , 2021, 161, 173-178.	0.6	34
715	Effectiveness of HPV vaccine by age at vaccination and number of doses: protocol for a population-based matched case-control study. <i>BMJ Open</i> , 2021, 11, e043093.	0.8	2

#	ARTICLE	IF	CITATIONS
716	Real-World Effectiveness of Human Papillomavirus Vaccination Against Cervical Cancer. <i>Journal of the National Cancer Institute</i> , 2021, 113, 1329-1335.	3.0	110
717	Cost-effectiveness analysis of the nonavalent human papillomavirus vaccine for the prevention of cervical cancer in Singapore. <i>Vaccine</i> , 2021, 39, 2255-2263.	1.7	5
718	Association of Inadvertent 9-Valent Human Papillomavirus Vaccine in Pregnancy With Spontaneous Abortion and Adverse Birth Outcomes. <i>JAMA Network Open</i> , 2021, 4, e214340.	2.8	15
719	Health Impact and Cost-Effectiveness of Implementing Gender-Neutral Vaccination With the 9-Valent Human Papillomavirus Vaccine in Belgium. <i>Frontiers in Pharmacology</i> , 2021, 12, 628434.	1.6	5
720	Human Papillomavirus Vaccination for Foreigners during COVID-19 Era. <i>Hang'gong Uju Uihaghojeji</i> , 2021, 31, 21-23.	0.2	2
721	The Immune Microenvironment in Human Papilloma Virus-Induced Cervical Lesions—Evidence for Estrogen as an Immunomodulator. <i>Frontiers in Cellular and Infection Microbiology</i> , 2021, 11, 649815.	1.8	27
722	Distribution of genetic alterations in high-risk early-stage cervical cancer patients treated with postoperative radiation therapy. <i>Scientific Reports</i> , 2021, 11, 10567.	1.6	7
723	Development and evaluation of a new non-competitive Luminex immunoassay detecting antibodies against human papillomavirus types 6, 11, 16 and 18. <i>Journal of General Virology</i> , 2021, 102, .	1.3	1
724	Parents willingness to vaccinate their daughter against human papilloma virus and its associated factors in Bench-Sheko zone, southwest Ethiopia. <i>Heliyon</i> , 2021, 7, e07051.	1.4	13
725	Vaccines for immunoprevention of cancer. <i>Journal of Clinical Investigation</i> , 2021, 131, .	3.9	39
726	Postpartum HPV Vaccination Rate and Differences in Background Characteristics Between HPV Vaccinated and Unvaccinated Postpartum Women: Strict Monitoring and Follow-Up of Postpartum HPV Vaccination Program. <i>Frontiers in Immunology</i> , 2021, 12, 626582.	2.2	2
727	Talking about recommended age or fewer doses: what motivates HPV vaccination timeliness?. <i>Human Vaccines and Immunotherapeutics</i> , 2021, 17, 3077-3080.	1.4	4
728	Randomised trials at the level of the individual. <i>The Lancet Global Health</i> , 2021, 9, e691-e700.	2.9	11
729	Immunogenicity and safety of a nine-valent human papillomavirus vaccine in women 27–45 years of age compared to women 16–26 years of age: An open-label phase 3 study. <i>Vaccine</i> , 2021, 39, 2800-2809.	1.7	23
730	HPV and Cytology Testing in Women Undergoing 9-Valent HPV Opportunistic Vaccination: A Single-Cohort Follow Up Study. <i>Vaccines</i> , 2021, 9, 643.	2.1	4
731	Anal cancer screening and prevention: a review for dermatologists. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2021, 35, 1622-1627.	1.3	6
732	Proteomics Analysis of Andrographolide-Induced Apoptosis via the Regulation of Tumor Suppressor p53 Proteolysis in Cervical Cancer-Derived Human Papillomavirus 16-Positive Cell Lines. <i>International Journal of Molecular Sciences</i> , 2021, 22, 6806.	1.8	5
733	Efficacy of a carrageenan gel in preventing anal human papillomavirus (HPV) infection: interim analysis of the Lubricant Investigation in Men to Inhibit Transmission of HPV Infection (LIMIT-HPV) randomised controlled trial. <i>Sexually Transmitted Infections</i> , 2021, , sextrans-2021-055009.	0.8	2

#	ARTICLE	IF	CITATIONS
734	Safety of vaccines used for routine immunization in the United States: An updated systematic review and meta-analysis. <i>Vaccine</i> , 2021, 39, 3696-3716.	1.7	26
735	HPV Genotyping by Molecular Mapping of Tissue Samples in Vaginal Intraepithelial Neoplasia (VaIN) and Vaginal Squamous Cell Carcinoma (VaSCC). <i>Cancers</i> , 2021, 13, 3260.	1.7	9
736	Design of a Phase III immunogenicity and safety study evaluating two-dose regimens of 9-valent human papillomavirus (9vHPV) vaccine with extended dosing intervals. <i>Contemporary Clinical Trials</i> , 2021, 105, 106403.	0.8	2
738	The projected cost-effectiveness and budget impact of HPV vaccine introduction in Ghana. <i>Vaccine</i> , 2022, 40, A85-A93.	1.7	12
739	Human papillomavirus genotyping predicts residual/recurrent disease after local treatment for cervical intraepithelial neoplasia better than viral <sc>DNA</sc> testing. <i>Journal of Obstetrics and Gynaecology Research</i> , 2021, 47, 3628-3633.	0.6	4
740	Risk-Benefit Analysis of the 9-Valent HPV Vaccination for Adolescent Boys from an Individual Perspective. <i>Japanese Journal of Infectious Diseases</i> , 2022, 75, 114-120.	0.5	1
741	Distribution of HPV genotypes among women with abnormal cytology results in Alberta, Canada. <i>Jammi</i> , 2021, 6, 94-103.	0.3	1
742	Benefits of Gender-Neutral Vaccination Strategy for the Prevention of HPV-Associated Diseases and the Eradication of HPV Infection in General. <i>Current State of HPV Vaccination in the World. PediatriĀeskaĀĉ FarmakologiĀĉ</i> , 2021, 18, 239-244.	0.1	1
743	A Framework for Cervical Cancer Elimination in Low-and-Middle-Income Countries: A Scoping Review and Roadmap for Interventions and Research Priorities. <i>Frontiers in Public Health</i> , 2021, 9, 670032.	1.3	25
744	Anogenital Human Papillomavirus (HPV) Infection, Seroprevalence, and Risk Factors for HPV Seropositivity Among Sexually Active Men Enrolled in a Global HPV Vaccine Trial. <i>Clinical Infectious Diseases</i> , 2022, 74, 1247-1256.	2.9	8
745	In Silico-Design and Immunological Studies of Two Novel Multiepitope DNA-Based Vaccine Candidates Against High-Risk Human Papillomaviruses. <i>Molecular Biotechnology</i> , 2021, 63, 1192-1222.	1.3	6
746	Incidence and Types of Human Papillomavirus Infections in Adolescent Girls and Young Women Immunized With the Human Papillomavirus Vaccine. <i>JAMA Network Open</i> , 2021, 4, e2121893.	2.8	11
747	Strategies to improve human papillomavirus (HPV) vaccination rates among college students. <i>Journal of American College Health</i> , 2023, 71, 2192-2199.	0.8	6
748	The comparative safety of human papillomavirus vaccines: A Bayesian network meta-analysis. <i>Journal of Medical Virology</i> , 2022, 94, 729-736.	2.5	7
749	Effectiveness of various human papillomavirus vaccination strategies: A community randomized trial in Finland. <i>Cancer Medicine</i> , 2021, 10, 7759-7771.	1.3	2
750	A Vax4HPV Mobile Application for Parents of Human Papillomavirus Vaccine-Eligible Children. <i>CIN - Computers Informatics Nursing</i> , 2022, 40, 455-465.	0.3	3
751	Treatment of Relapsing HPV Diseases by Restored Function of Natural Killer Cells. <i>New England Journal of Medicine</i> , 2021, 385, 921-929.	13.9	22
752	Cervical cancer prevention and control in women living with human immunodeficiency virus. <i>Ca-A Cancer Journal for Clinicians</i> , 2021, 71, 505-526.	157.7	70



#	ARTICLE	IF	CITATIONS
753	Single-dose HPV vaccination efficacy among adolescent girls and young women in Kenya (the KEN SHE) Tj ETQq0 0,0,rgBT /Oyerlock 10	0.7	23
754	The Catastrophic HPV/HIV Dual Viral Oncogenomics in Concert with Dysregulated Alternative Splicing in Cervical Cancer. <i>International Journal of Molecular Sciences</i> , 2021, 22, 10115.	1.8	14
755	Nonavalent HPV vaccine's cost-effectiveness for Norway remains to be determined. <i>Preventive Medicine</i> , 2021, 150, 106662.	1.6	0
756	Precision Prevention: The 2019 ASCCP Risk-Based Management Consensus Guidelines for Abnormal Cervical Cancer Screening Tests and Cancer Precursors. <i>Journal of Molecular Pathology</i> , 2021, 2, 274-280.	0.5	1
757	Trends in Human Papillomavirus Vaccine Safety Concerns and Adverse Event Reporting in the United States. <i>JAMA Network Open</i> , 2021, 4, e2124502.	2.8	58
758	Prevalence and Genotype Distribution of Human Papillomavirus Infection among 12 076 Iranian Women. <i>International Journal of Infectious Diseases</i> , 2021, 111, 295-302.	1.5	7
759	Prevention and Screening of HPV Malignancies. <i>Seminars in Radiation Oncology</i> , 2021, 31, 297-308.	1.0	5
760	Immunological responses and anti-tumor effects of HPV16/18 L1-L2-E7 multiepitope fusion construct along with curcumin and nanocurcumin in C57BL/6 mouse model. <i>Life Sciences</i> , 2021, 285, 119945.	2.0	2
761	Design and methods for the Carrageenan-gel Against Transmission of Cervical Human papillomavirus (CATCH) study: A randomized controlled trial. <i>Contemporary Clinical Trials</i> , 2021, 110, 106560.	0.8	3
762	Intraepithelial neoplasia of the lower genital tract (cervix, vagina, vulva). , 2022, , 637-647.e2.		0
763	Recalcitrant giant genital wart treated with the combination of measlesâ€“mumpsâ€“rubella vaccine and human papillomavirus vaccine. <i>Dermatologica Sinica</i> , 2021, 39, 141.	0.2	0
764	Challenges of Human Papillomavirus Infection in Solid Organ and Hematopoietic Stem Cell Transplant Recipients. , 2021, , 833-858.		0
765	Environmental and Genetic Factors Contributing to Bladder Carcinogenesis. , 2021, , 13-44.		1
766	Human Papillomavirus Vaccines. , 2021, , 147-157.		0
767	Cervical Cancer Prevention. , 2019, , 629-652.		2
768	Human Acute and Chronic Viruses: Host-Pathogen Interactions and Therapeutics. , 2020, , 1-120.		3
769	Vaccination Strategies for the Control and Treatment of HPV Infection and HPV-Associated Cancer. <i>Recent Results in Cancer Research</i> , 2021, 217, 157-195.	1.8	20
770	Impfen bei Immundefizienz. , 2018, 61, 1034.		3

#	ARTICLE	IF	CITATIONS
771	A National Survey of Canadian Physicians on HPV: Knowledge, Barriers, and Preventive Practices. <i>Journal of Obstetrics and Gynaecology Canada</i> , 2019, 41, 599-607.e3.	0.3	10
772	Impact of HPV vaccination and cervical screening on cervical cancer elimination: a comparative modelling analysis in 78 low-income and lower-middle-income countries. <i>Lancet, The</i> , 2020, 395, 575-590.	6.3	421
773	Mortality impact of achieving WHO cervical cancer elimination targets: a comparative modelling analysis in 78 low-income and lower-middle-income countries. <i>Lancet, The</i> , 2020, 395, 591-603.	6.3	321
774	Cancer incidence in English children, adolescents and young people: past trends and projections to 2030. <i>British Journal of Cancer</i> , 2017, 117, 1865-1873.	2.9	11
775	Recurring infection with ecologically distinct HPV types can explain high prevalence and diversity. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2017, 114, 13573-13578.	3.3	59
776	Immunogenicity and Safety of the 9-Valent Human Papillomavirus Vaccine in Solid Organ Transplant Recipients and Adults Infected With Human Immunodeficiency Virus (HIV). <i>Clinical Infectious Diseases</i> , 2021, 73, e661-e671.	2.9	20
777	Impact of naturally occurring variation in the human papillomavirus (HPV) 33 capsid proteins on recognition by vaccine-induced cross-neutralizing antibodies. <i>Journal of General Virology</i> , 2017, 98, 1755-1761.	1.3	12
779	Human papillomavirus genotype contribution to cervical cancer and precancer: Implications for screening and vaccination in Japan. <i>Cancer Science</i> , 2020, 111, 2546-2557.	1.7	22
780	Whole-Genome Sequencing and Variant Analysis of Human Papillomavirus 16 Infections. <i>Journal of Virology</i> , 2017, 91, .	1.5	33
781	Vaginal high-risk human papillomavirus infection in a cross-sectional study among women of six different ethnicities in Amsterdam, the Netherlands: the HELIUS study. <i>Sexually Transmitted Infections</i> , 2016, 92, 611-618.	0.8	6
782	Are we there yet? The never-ending quest for an Epstein-Barr virus vaccine. <i>Journal of Clinical Investigation</i> , 2019, 129, 1836-1838.	3.9	4
783	HPV vaccination to prevent cervical cancer and other HPV-associated disease: from basic science to effective interventions. <i>Journal of Clinical Investigation</i> , 2016, 126, 5-11.	3.9	65
784	Epidemiologic Evaluation of Human Papillomavirus Type Competition and the Potential for Type Replacement Post-Vaccination. <i>PLoS ONE</i> , 2016, 11, e0166329.	1.1	17
785	Cervical HPV type-specific pre-vaccination prevalence and age distribution in Croatia. <i>PLoS ONE</i> , 2017, 12, e0180480.	1.1	14
786	The prevalence of human papillomavirus in oropharyngeal cancer in a New Zealand population. <i>PLoS ONE</i> , 2017, 12, e0186424.	1.1	14
787	Cervical Human Papillomavirus genotypes in HIV-infected women: a cross-sectional analysis of the VALHIDATE study. <i>Journal of Preventive Medicine and Hygiene</i> , 2017, 58, E259-E265.	0.9	10
788	Three-Year Follow-up of 2-Dose Versus 3-Dose HPV Vaccine. <i>Pediatrics</i> , 2021, 147, .	1.0	11
789	Recent advances in prophylactic human papillomavirus (HPV) vaccination: a review of key literature published between September 2017 and September 2018. <i>Acta Dermatovenerologica Alpina, Panonica Et Adriatica</i> , 2018, 27, .	0.1	3

#	ARTICLE	IF	CITATIONS
790	Sexually Transmitted Infections: Impact and Cost-Effectiveness of Prevention. , 2017, , 203-232.		26
791	Alternative HPV vaccination schedules in Latin America. Salud Publica De Mexico, 2018, 60, 693.	0.1	2
792	Universal Human Papillomavirus Vaccination and its Impact on the Southern Italian Region. Current Pharmaceutical Design, 2020, 26, 343-357.	0.9	3
793	Cervical Cancer Prevention Through HPV Vaccination in Low- and Middle-Income Countries in Asia. Asian Pacific Journal of Cancer Prevention, 2017, 18, 2339-2343.	0.5	15
795	The impact of 10 years of human papillomavirus (HPV) vaccination in Australia: what additional disease burden will a nonavalent vaccine prevent?. Eurosurveillance, 2018, 23, .	3.9	179
796	Cost-Effectiveness Analysis of Human Papillomavirus Vaccination in Adolescent Girls in Taiwan. Asian Pacific Journal of Cancer Prevention, 2019, 20, 1377-1387.	0.5	11
797	Scientific evidence supporting recommendations on the use of the 9-valent HPV vaccine in a 2-dose vaccine schedule in Australia. Communicable Diseases Intelligence (2018), 2020, 44, .	0.3	6
798	Efficacy of HPV Vaccination in Women Receiving LEEP for Cervical Dysplasia: A Single Institution's Experience. Vaccines, 2020, 8, 45.	2.1	27
799	Cervical cancer in low and middle-income countries (Review). Oncology Letters, 2020, 20, 2058-2074.	0.8	185
801	HPV vaccine: One, two, or three doses for cervical cancer prevention?. Indian Journal of Medical and Paediatric Oncology, 2015, 36, 201-206.	0.1	13
802	Current global status & impact of human papillomavirus vaccination: Implications for India. Indian Journal of Medical Research, 2016, 144, 169.	0.4	19
803	Newer vaccines (measles-rubella, human papillomavirus, rotavirus, and pneumococcal conjugate) Tj ETQq1 1 0.784314 rgBT /Overl... Diseases, 2018, 3, 25.	0.4	1
804	The Impact of High-Risk HPV Genotypes Other Than HPV 16/18 on the Natural Course of Abnormal Cervical Cytology: A Korean HPV Cohort Study. Cancer Research and Treatment, 2016, 48, 1313-1320.	1.3	20
805	Prevention of Cervical Cancer. Journal of Cancer Therapy, 2018, 09, 79-88.	0.1	4
806	HPV Infection and Cervical Abnormalities in HIV Positive Women in Different Regions of Brazil, a Middle-Income Country. Asian Pacific Journal of Cancer Prevention, 2016, 16, 8085-8091.	0.5	6
807	Endometrial and Cervical Cancers. UNIPA Springer Series, 2021, , 885-922.	0.1	0
808	Why to vaccinate boys against papillomaviruses?. Pediatrie Pro Praxi, 2021, 22, 263-267.	0.1	0
809	Design of a phase III efficacy, immunogenicity, and safety study of 9-valent human papillomavirus vaccine in prevention of oral persistent infection in men. Contemporary Clinical Trials, 2022, 115, 106592.	0.8	15

#	ARTICLE	IF	CITATIONS
811	The tumor immune microenvironments of <sup>+</sup> and <sup>^</sup> head and neck cancers. WIREs Mechanisms of Disease, 2022, 14, e1539.	1.5	13
813	Human Papillomaviruses. , 2015, , 15-43.		0
814	Prevention of Iatrogenic Cervical Cancer. Open Journal of Obstetrics and Gynecology, 2015, 05, 775-783.	0.1	1
815	Chapter 10: Prevention of Pregnancy and Sexually Transmitted Infections. , 2015, , .		0
816	Additional Guidance Online for Providers Regarding 9-Valent HPV Vaccine Use Among Persons Who Previously Received HPV Vaccination. Morbidity and Mortality Weekly Report, 2015, 64, 806-806.	9.0	3
817	Prevalence of Human Papilloma Virus Infection in Young Primiparous Women During Postpartum Period: Study from a Tertiary Care Center in Northern India. Journal of Clinical and Diagnostic Research JCDR, 2016, 10, QC06-QC09.	0.8	0
818	Management of Cervical Dysplasia. , 2016, , 1-11.		0
819	Cervical Cancer Screening at a Crossroads: Learnings from the Past Driving Change for the Future. , 0, , .		0
820	Human Papillomavirus Vaccines. , 2017, , 127-136.		0
822	Prevention of Cervical Cancer: Era of HPV Testing and Vaccination. Comprehensive Gynecology and Obstetrics, 2017, , 87-99.	0.0	0
823	Management of Cervical Dysplasia. , 2017, , 865-875.		2
825	Neue Arzneimittel 2016. , 2017, , 55-135.		0
826	Carcinogenesis in the Epithelium of the Upper Aerodigestive Tract. , 2017, , 185-190.		0
827	Prevention of Complications from Human Papillomavirus Infection in the HIV-Infected Individual. , 2017, , 141-163.		0
828	Control and Prevention in Cervical Cancer. , 2017, , 87-97.		0
832	Human Papillomavirus Vaccination: Making Sense of the Public Controversy. , 2018, , 59-94.		0
833	Human Papillomavirus and Head and Neck Cancer. , 2018, , 349-364.		0
836	The effect of a booster dose of HPV tetravalent vaccine after 51 months: implications for extended vaccination schedules. Salud Publica De Mexico, 2018, 60, 666.	0.1	2

#	ARTICLE	IF	CITATIONS
837	Students'™ knowledge about cervical cancer and vaccine against human papillomavirus (HPV). OnCORReview, 2019, 8, 127-136.	0.1	0
840	HPV Knowledge and Attitudes Among American Indian and Alaska Native Health and STEM Conference Attendees. International Journal of Indigenous Health, 2019, 14, 205-221.	0.8	4
841	Estado actual de las nuevas indicaciones de la vacuna del papiloma humano. FMC Formacion Medica Continuada En Atencion Primaria, 2019, 26, 459-463.	0.0	0
842	Human papillomavirus vaccination: review of the current evidence. Mucosa, 2019, 2, 86-94.	0.3	1
843	HPV Vaccines: An Important Tool for STI Prevention. , 2020, , 375-389.		0
844	The impact of the HPV vaccine on the world: initial outcomes and challenges. Jornal Brasileiro De DoenÇas Sexualmente TransmissÃveis, 0, 32, .	0.1	1
846	HPV vaccine development after more than ten years approval. Majalah Obstetri Dan Ginekologi, 2020, 28, 39.	0.1	0
847	PAPILLOMAVIRAL CARCINOGENESIS. MAJOR ACHIEVEMENTS AND CERTAIN CHALLENGES PART 2. HPV-ASSOCIATED CANCERS IN RUSSIA. PREVENTIVE HPV VACCINES. , 2020, 19, 31-38.	0.3	3
848	Viral Causality of Human Cancer and Potential Roles of Human Endogenous Retroviruses in the Multi-Omics Era: An Evolutionary Epidemiology Review. Frontiers in Oncology, 2021, 11, 687631.	1.3	9
849	Intrauterine device and cervical cancer. Majalah Obstetri Dan Ginekologi, 2020, 28, 140.	0.1	0
852	Challenges of Human Papillomavirus Infection in Solid Organ and Hematopoietic Stem Cell Transplant Recipients. , 2020, , 1-26.		0
853	Prinzipien der primÃren PrÃvention von Krebserkrankungen. Springer Reference Medizin, 2020, , 1-14.	0.0	0
855	Knowledge level and attitude for Human Papillomavirus (HPV) infection and HPV vaccines among medical school students. Journal of Contemporary Medicine, 2020, 10, 394-398.	0.1	3
857	Use of 9-valent human papillomavirus (HPV) vaccine: updated HPV vaccination recommendations of the advisory committee on immunization practices. Morbidity and Mortality Weekly Report, 2015, 64, 300-4.	9.0	581
858	Update on the new 9-valent vaccine for human papillomavirus prevention. Canadian Family Physician, 2016, 62, 399-402.	0.1	28
859	Association between Human Papillomavirus and Non-cervical Genital Cancers in Brazil: A Systematic Review and Meta-Analysis. Asian Pacific Journal of Cancer Prevention, 2018, 19, 2359-2371.	0.5	5
860	The nonavalent vaccine: a review of high-risk HPVs and a plea to the CDC. American Journal of Stem Cells, 2019, 8, 52-64.	0.4	9
861	Cross-Protective IgG and IgA Antibodies against Oncogenic and Non-Oncogenic HPV Genotypes. Asian Pacific Journal of Cancer Prevention, 2020, 21, 2799-2804.	0.5	0

#	ARTICLE	IF	CITATIONS
862	A Study of Human Papillomavirus Genotypes Specificity and the Vaccines Introducing System for Korean-Chinese Women in the Yanbian Autonomous Region. <i>Asian Pacific Journal of Cancer Prevention</i> , 2020, 21, 3331-3338.	0.5	0
863	Cervical cancer screening varies by HPV vaccination status among a National Cohort of privately insured young women in the United States 2006-2016. <i>Medicine (United States)</i> , 2021, 100, e27457.	0.4	0
864	Perceived Barriers and Facilitators in Accessing Cervical Cancer Screening. <i>Family and Community Health</i> , 2022, 45, 46-57.	0.5	3
865	Cancer Vaccine in Solid Tumors: Where We Stand. <i>Indian Journal of Medical and Paediatric Oncology</i> , 2021, 42, 319-324.	0.1	0
866	Cervical cancer screening varies by HPV vaccination status among a National Cohort of privately insured young women in the United States 2006-2016. <i>Medicine (United States)</i> , 2021, 100, e27457.	0.4	4
867	Immunogenicity and safety of the human papillomavirus vaccine in young survivors of cancer in the USA: a single-arm, open-label, phase 2, non-inferiority trial. <i>The Lancet Child and Adolescent Health</i> , 2022, 6, 38-48.	2.7	7
868	Human Papillomavirus Vaccine Efficacy and Effectiveness against Cancer. <i>Vaccines</i> , 2021, 9, 1413.	2.1	77
869	HPV Immunization. , 2021, , 457-466.		0
870	HPV-Impfung: Sehr effektiv – aber immer noch vernachlässigt. , 0, , .		0
871	Analysis of cervical cancer mortality rate trends in Natal-RN, Brazil, between 2000 and 2012. <i>Revista De Salud Publica</i> , 2019, 21, 161-167.	0.0	4
872	Cross-Protective IgG and IgA Antibodies against Oncogenic and Non-Oncogenic HPV Genotypes. <i>Asian Pacific Journal of Cancer Prevention</i> , 2020, 21, 2799-2804.	0.5	3
873	Vacuna contra el virus del papiloma humano. <i>Revista Medica Sinergia</i> , 2020, 5, e475.	0.0	0
874	HPV-assozierte Neoplasien: Wie die Impfprävention gefördert werden kann. , 0, , .		0
875	A Study of Human Papillomavirus Genotypes Specificity and the Vaccines Introducing System for Korean-Chinese Women in the Yanbian Autonomous Region. <i>Asian Pacific Journal of Cancer Prevention</i> , 2020, 21, 3331-3338.	0.5	0
876	HPV Vaccination: Polish-Language Facebook Discourse Analysis. <i>International Journal of Environmental Research and Public Health</i> , 2022, 19, 914.	1.2	2
877	Provider response and follow-up to parental declination of HPV vaccination. <i>Vaccine</i> , 2022, 40, 344-350.	1.7	2
878	Immunogenicity of a Two-Dose Human Papillomavirus Vaccine Schedule in HIV-Infected Adolescents with Immune Reconstitution. <i>Vaccines</i> , 2022, 10, 118.	2.1	3
879	The distribution and pathogenic risk of non-9-valent vaccine covered HPV subtypes in cervical lesions. <i>Cancer Medicine</i> , 2022, 11, 1542-1552.	1.3	2

#	ARTICLE	IF	CITATIONS
880	Knowledge, Attitude, and Practice of Cervical Cancer Screening, and HPV Vaccination: A Cross-Sectional Study Among Obstetricians and Gynecologists in Egypt. <i>Maternal and Child Health Journal</i> , 2022, 26, 565.	0.7	2
881	Extracellular vesicles mediated proinflammatory macrophage phenotype induced by radiotherapy in cervical cancer. <i>BMC Cancer</i> , 2022, 22, 88.	1.1	10
882	What influences parents to vaccinate (or not) their sons with the Human Papillomavirus (HPV) vaccine: an examination of HPV vaccine decision-making changes over time. <i>Journal of Psychosocial Oncology Research and Practice</i> , 2022, 4, e068.	0.2	1
883	An Update on Human Papilloma Virus Vaccines: History, Types, Protection, and Efficacy. <i>Frontiers in Immunology</i> , 2021, 12, 805695.	2.2	44
884	Cervical Intraepithelial Neoplasia 3 (Cervical Intraepithelial Neoplasia 3/High-Grade Squamous) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50 587 Center. <i>Journal of Lower Genital Tract Disease</i> , 2022, Publish Ahead of Print, .	0.9	0
885	Vaccin grippal haute dose: un vaccin adaptÃ© aux 65 ans et plus. <i>La Presse MÃ©dicale Formation</i> , 2022, 3, 105-105.	0.1	0
886	HPV vaccination among seropositive, DNA negative cohorts: a systematic review & meta-analysis. <i>Journal of Gynecologic Oncology</i> , 2022, 33, .	1.0	3
887	Human papillomavirus (HPV) infection and vaccination: A cross-sectional study of college studentsâ€™ knowledge, awareness, and attitudes in Villanova, PA. <i>Vaccine: X</i> , 2022, 10, 100141.	0.9	8
888	Cancer Immunotherapies: What the Perioperative Physician Needs to Know. <i>Current Oncology Reports</i> , 2022, 24, 399-414.	1.8	6
889	Long-Term Effects of Human Papillomavirus Vaccination in Clinical Trials and Real-World Data: A Systematic Review. <i>Vaccines</i> , 2022, 10, 256.	2.1	4
890	A puzzle of proportions: Two popular Bayesian tests can yield dramatically different conclusions. <i>Statistics in Medicine</i> , 2022, 41, 1319-1333.	0.8	8
891	Effectiveness of Prophylactic Human Papillomavirus Vaccine in the Prevention of Recurrence in Women Conized for HSIL/CIN 2-3: The VENUS Study. <i>Vaccines</i> , 2022, 10, 288.	2.1	9
893	Protection to Self and to One's Sexual Partner After Human Papillomavirus Vaccination: Preliminary Analysis From the Transmission Reduction And Prevention with HPV Vaccination Study. <i>Sexually Transmitted Diseases</i> , 2022, 49, 414-422.	0.8	1
894	The role of the microbiome in the contribution of progression in cervical neoplasms. <i>K'art'veli Mec'nierebi</i> , 0, , .	0.0	0
896	How Can We Pursue Equity in Cervical Cancer Prevention With Existing HPV Genotype Differences?. <i>Journal of the National Cancer Institute</i> , 2022, 114, 787-789.	3.0	2
897	Cost-effectiveness of human papillomavirus vaccination in girls living in Latin American countries: A systematic review and meta-analysis. <i>Vaccine</i> , 2022, , .	1.7	2
898	Anal and cervical human papillomavirus genotypes in women co-infected with human immunodeficiency virus: A systematic review. <i>International Journal of STD and AIDS</i> , 2022, 33, 530-543.	0.5	3
899	Modeling the health and economic implications of adopting a 1-dose 9-valent human papillomavirus vaccination regimen in a high-income country setting: An analysis in the United Kingdom. <i>Vaccine</i> , 2022, 40, 2173-2183.	1.7	4

#	ARTICLE	IF	CITATIONS
900	Genotype-specific high-risk human papillomavirus infections and risk factors for cervical dysplasia in women with human immunodeficiency virus in Germany: results from a single-center cross-sectional study. <i>International Journal of Gynecological Cancer</i> , 2022, 32, 716-723.	1.2	3
901	Identifying a Single Optimal Integrated Cervical Cancer Prevention Policy in Norway: A Cost-Effectiveness Analysis. <i>Medical Decision Making</i> , 2022, 42, 795-807.	1.2	3
903	Human Papillomavirus Vaccination Initiation and Completion Among Heterosexual and Sexual Minority U.S. Adults. <i>LGBT Health</i> , 2022, 9, 177-185.	1.8	1
904	Human papillomavirus prevalence in male and female university students in Gaborone, Botswana. <i>Epidemiology and Infection</i> , 2022, 150, 1-25.	1.0	3
905	Prevalence of vaginal HPV infection among adolescent and early adult girls in Jos, North-Central Nigeria. <i>BMC Infectious Diseases</i> , 2022, 22, 340.	1.3	5
907	Clearance of HR-HPV within one year after focused ultrasound or loop electrosurgical excision procedure in patients with HSIL under 30. <i>International Journal of Hyperthermia</i> , 2022, 39, 15-21.	1.1	7
908	Vaccine Strategies for Human Papillomavirus-Associated Head and Neck Cancers. <i>Cancers</i> , 2022, 14, 33.	1.7	17
909	Human papillomavirus prevalence and genotype distribution in Vietnamese male patients between 2016 and 2020. <i>Journal of Medical Virology</i> , 2022, 94, 2892-2896.	2.5	6
910	Human Papillomavirus (HPV) Entry Inhibitors. <i>Advances in Experimental Medicine and Biology</i> , 2022, 1366, 223-239.	0.8	0
911	İnsan Papilloma Virüsü (HPV) ve Kullanım Sonrası Toplumsal Etkileri. <i>Özdeğeri Baysal Tıp Fakültesi Dergisi</i> , 0, , .	0,0	2
912	Male Circumcision and Genital Human Papillomavirus (HPV) Infection in Males and Their Female Sexual Partners: Findings From the HPV Infection and Transmission Among Couples Through Heterosexual Activity (HITCH) Cohort Study. <i>Journal of Infectious Diseases</i> , 2022, 226, 1184-1194.	1.9	2
913	Efficacy of Single-Dose Human Papillomavirus Vaccination among Young African Women. , 2022, 1, .		69
914	Development of a Nomogram Predicting the Risk of Persistence/Recurrence of Cervical Dysplasia. <i>Vaccines</i> , 2022, 10, 579.	2.1	27
915	Reimagining patient-centric cancer clinical trials: a multi-stakeholder international coalition. <i>Nature Medicine</i> , 2022, 28, 620-626.	15.2	13
916	A Review of Ethical and Legal Aspects of Gender-Neutral Human Papillomavirus Vaccination. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2022, 31, 919-931.	1.1	3
918	Development of HPV58 type-specific antibodies and detection kit. <i>Preparative Biochemistry and Biotechnology</i> , 2023, 53, 223-229.	1.0	1
920	The Quest to Eradicate HPV-Related Oropharyngeal Carcinoma: An Opportunity Not to Miss. <i>Journal of the National Cancer Institute</i> , 2022, 114, 1333-1337.	3.0	5
921	Attitudes and behaviors of obstetricians and gynecologists toward HPV vaccination: a 7-year follow-up survey in Japan. <i>International Journal of Clinical Oncology</i> , 2022, 27, 1356-1363.	1.0	1



#	ARTICLE	IF	CITATIONS
922	Immunogenicity and safety of the 9-valent human papillomavirus vaccine in Chinese females 9-45 years of age: A phase 3 open-label study. <i>Vaccine</i> , 2022, 40, 3263-3271.	1.7	5
923	B Cell Responses upon Human Papillomavirus (HPV) Infection and Vaccination. <i>Vaccines</i> , 2022, 10, 837.	2.1	7
924	HPV and HIV Coinfection in Women from a Southeast Region of Romania- PICOPV Study. <i>Medicina (Lithuania)</i> , 2022, 58, 760.	0.8	5
925	The implications of cell-free DNAs derived from tumor viruses as biomarkers of associated cancers. <i>Journal of Medical Virology</i> , 2022, 94, 4677-4688.	2.5	2
927	RG2-VLP: a Vaccine Designed to Broadly Protect against Anogenital and Skin Human Papillomaviruses Causing Human Cancer. <i>Journal of Virology</i> , 2022, 96, .	1.5	9
928	Current Status of Human Papillomavirus Infection and Cervical Cancer in the Philippines. <i>Frontiers in Medicine</i> , 0, 9, .	1.2	8
929	Designing of multi-epitope chimeric vaccine using immunoinformatic platform by targeting oncogenic strain HPV 16 and 18 against cervical cancer. <i>Scientific Reports</i> , 2022, 12, .	1.6	9
930	Self-emulsifying System Co-loaded with Paclitaxel and Coix Seed Oil Deeply Penetrated to Enhance Efficacy in Cervical Cancer. <i>Current Drug Delivery</i> , 2023, 20, 919-926.	0.8	6
931	Myths and fake messages about human papillomavirus (HPV) vaccination: answers from the ESGO Prevention Committee. <i>International Journal of Gynecological Cancer</i> , 0, , ijgc-2022-003685.	1.2	4
932	Prophylactic and Therapeutic HPV Vaccines: Current Scenario and Perspectives. <i>Frontiers in Cellular and Infection Microbiology</i> , 0, 12, .	1.8	33
933	Safety and immunogenicity of an <i>Escherichia coli</i> -produced bivalent human papillomavirus type 6/11 vaccine: A dose-escalation, randomized, double-blind, placebo-controlled phase 1 trial. <i>Human Vaccines and Immunotherapeutics</i> , 2022, 18, .	1.4	2
934	Motivators and Barriers to HPV Vaccination: A Qualitative Study of Underserved Women Attending Planned Parenthood. <i>Vaccines</i> , 2022, 10, 1126.	2.1	1
935	Single-dose HPV vaccine immunity: is there a role for non-neutralizing antibodies?. <i>Trends in Immunology</i> , 2022, 43, 815-825.	2.9	6
936	The HPV Induced Cancer Resource (THInCR): a Suite of Tools for Investigating HPV-Dependent Human Carcinogenesis. <i>MSphere</i> , 2022, 7, .	1.3	5
937	Combination therapy between prophylactic and therapeutic human papillomavirus (HPV) vaccines with special emphasis on implementation of nanotechnology. <i>Microbial Pathogenesis</i> , 2022, 171, 105747.	1.3	3
938	Systematic review of the use of human papillomavirus vaccine as adjuvant therapy for juvenile-onset recurrent respiratory papillomatosis. <i>International Journal of Pediatric Otorhinolaryngology</i> , 2022, 162, 111314.	0.4	4
939	The Clinical and Economic Impact of a Nonavalent Versus Bivalent Human Papillomavirus National Vaccination Program in Taiwan. <i>Value in Health Regional Issues</i> , 2022, 32, 79-87.	0.5	2
940	Clinical Development of mRNA Vaccines: Challenges and Opportunities. <i>Current Topics in Microbiology and Immunology</i> , 2022, , 167-186.	0.7	2

#	ARTICLE	IF	CITATIONS
941	HPV genotyping by L1 amplicon sequencing of archived invasive cervical cancer samples: a pilot study. <i>Infectious Agents and Cancer</i> , 2022, 17, .	1.2	2
942	Implementation of a provider-focused intervention for maximizing human papillomavirus (HPV) vaccine uptake in young cancer survivors receiving follow-up care in pediatric oncology practices: protocol for a cluster-randomized trial of the HPV PROTECT intervention. <i>BMC Pediatrics</i> , 2022, 22, .	0.7	3
944	Healthcare Provider Recommendations and Observed Changes in HPV Vaccination Acceptance during the COVID-19 Pandemic. <i>Vaccines</i> , 2022, 10, 1515.	2.1	2
945	Enhanced Immunogenicity of Adjuvanted Microparticulate HPV16 Vaccines Administered via the Transdermal Route. <i>Pharmaceuticals</i> , 2022, 15, 1128.	1.7	1
946	Safety of AS04â€HPVâ€16/18 vaccine in Chinese women aged 26 years and older and longâ€term protective effect in women vaccinated at age 18â€25 years: A 10â€year followâ€up study. <i>Asia-Pacific Journal of Clinical Oncology</i> , 0, , .	0.7	1
947	Governing HPV-related carcinoma using vaccines: Bottlenecks and breakthroughs. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	6
948	Association between serum vitamin C and HPV infection in American women: a cross-sectional study. <i>BMC Women's Health</i> , 2022, 22, .	0.8	2
949	A bacterially expressed triple-type chimeric vaccine against human papillomavirus types 51, 69, and 26. <i>Vaccine</i> , 2022, 40, 6141-6152.	1.7	4
950	HPV vaccination and HPV-related malignancies: impact, strategies and optimizations toward global immunization coverage. <i>Cancer Treatment Reviews</i> , 2022, 111, 102467.	3.4	9
951	An integrative approach toward identification and analysis of therapeutic targets involved in HPV pathogenesis with a focus on carcinomas. <i>Cancer Biomarkers</i> , 2022, , 1-22.	0.8	2
952	Association between Prestored Smartphone Monitored Physical Activity and the Risk of HPV Infection and Cervical Cancer. <i>Asian Pacific Journal of Cancer Prevention</i> , 2022, 23, 3393-3404.	0.5	1
953	Identification of human MHC-I HPV18 E6/E7-specific CD8â€%+â€%T cell epitopes and generation of an HPV18 E6/E7-expressing adenosquamous carcinoma in HLA-A2 transgenic mice. <i>Journal of Biomedical Science</i> , 2022, 29, .	2.6	1
954	The Effects of Human Papillomavirus Infection and Vaccination on Cardiovascular Diseases, NHANES 2003-2016. <i>American Journal of Medicine</i> , 2023, 136, 294-301.e2.	0.6	5
956	Improving cervical cancer survivalâ€A multifaceted strategy to sustain progress for this global problem. <i>Cancer</i> , 2022, 128, 4074-4084.	2.0	3
957	Comparison of Breast Cancer and Cervical Cancer in Uzbekistan and Korea: The First Report of The Uzbekistanâ€Korea Oncology Consortium. <i>Medicina (Lithuania)</i> , 2022, 58, 1428.	0.8	3
958	Factors affecting childrenâ€™s HPV vaccination in Austria: Evidence from a parent survey. <i>Human Vaccines and Immunotherapeutics</i> , 2022, 18, .	1.4	2
959	Awareness, perceptions, and choices of physicians pertaining to human papillomavirus (HPV) vaccination in India: A formative research study. <i>Vaccine: X</i> , 2022, 12, 100228.	0.9	3
960	Prevention of Cervical Cancer in Low-Resource African Settings. <i>Obstetrics and Gynecology Clinics of North America</i> , 2022, 49, 771-781.	0.7	6

#	ARTICLE	IF	CITATIONS
961	Cervical cancer in Nepal: Current screening strategies and challenges. <i>Frontiers in Public Health</i> , 0, 10, .	1.3	8
962	Cost-effectiveness and epidemiological impact of gender-neutral HPV vaccination in Spain. <i>Human Vaccines and Immunotherapeutics</i> , 2022, 18, .	1.4	5
963	Safety of 9-valent human papillomavirus vaccine administered to males and females in routine use. <i>Vaccine</i> , 2023, 41, 1819-1825.	1.7	5
964	Autoimmunity in patients reporting long-term complications after exposure to human papilloma virus vaccination. <i>Journal of Autoimmunity</i> , 2022, 133, 102921.	3.0	1
965	Features of human papillomavirus vaccination education strategies in low- and middle-income countries: a scoping review. <i>Public Health</i> , 2022, 213, 61-67.	1.4	2
966	Genital infection by Human papillomavirus (HPV) in women from Santa Catarina/Brazil. <i>Jornal Brasileiro De DoenÇas Sexualmente TransmissÁveis</i> , 0, 34, .	0.1	1
967	Progress of research on human papilloma virus vaccine application. , 0, 19, 142-147.		0
968	Recent Advances in Cancer Vaccines: Challenges, Achievements, and Futuristic Prospects. <i>Vaccines</i> , 2022, 10, 2011.	2.1	20
969	Skin as an immune organ and the site of biomimetic, non-invasive vaccination. <i>Medicine in Novel Technology and Devices</i> , 2022, 16, 100196.	0.9	3
971	HPV-associated Dysplasia of Skin and Mucosa and Vaccination Options in Trans People. , 2022, , 267-270.		0
972	Cost of illness in a super-aged societyâ€™comparison of breast, lung, and prostate cancer in Japan. <i>BMC Geriatrics</i> , 2022, 22, .	1.1	3
974	Human Papillomavirus: Challenges and Opportunities for the Control of Cervical Cancer. <i>Archives of Medical Research</i> , 2022, 53, 753-769.	1.5	10
975	Barriers and supports for uptake of human papillomavirus vaccination in Indigenous people globally: A systematic review. <i>PLOS Global Public Health</i> , 2023, 3, e0001406.	0.5	5
976	The Future of Cervical Cancer Prevention: From â€™One-Size-Fits-Allâ€™to Personalized Screening. <i>Journal of Personalized Medicine</i> , 2023, 13, 161.	1.1	2
977	Assessment of Saudi Femalesâ€™ Knowledge Regarding Human Papillomavirus Infection, Screening, and Available Methods for Prevention: A Cross-Sectional Study in Qassim Region. <i>Cureus</i> , 2023, , .	0.2	0
978	Maternal human papillomavirus infection during pregnancy and preterm delivery, a motherâ€™child cohort study in Norway and Sweden. <i>Acta Obstetricia Et Gynecologica Scandinavica</i> , 0, , .	1.3	2
979	Prevalence and genotype distribution of human papillomavirus infections in Beijing, China between 2016 and 2020. <i>Virology Journal</i> , 2023, 20, .	1.4	7
980	Human Papillomavirusâ€™Associated Head and Neck Malignancies in Sub-Saharan Africa: A Systematic Review. <i>JCO Global Oncology</i> , 2023, , .	0.8	3

#	ARTICLE	IF	CITATIONS
981	Associated factors to human papillomavirus vaccine adhesion in adult women: a cross-sectional study. <i>Porto Biomedical Journal</i> , 2023, 8, e181.	0.4	0
982	School-based HPV Vaccination: Variation in Inter-school Vaccine Uptake not Influenced by the Introduction of a New Information Brochure. <i>Asian Pacific Journal of Cancer Prevention</i> , 2023, 24, 249-255.	0.5	0
983	Impact of the COVID-19 Pandemic on HPV Vaccinations in Switzerland and Greece: Road to Recovery. <i>Vaccines</i> , 2023, 11, 258.	2.1	4
984	Healthcare Provider's Perceived Self-Efficacy in HPV Vaccination Hesitancy Counseling and HPV Vaccination Acceptance. <i>Vaccines</i> , 2023, 11, 300.	2.1	2
985	Abnormal Findings of the Cervix. , 2023, , 13-54.		0
986	Maximizing the cost-effectiveness of cervical screening in the context of routine HPV vaccination by optimizing screening strategies with respect to vaccine uptake: a modeling analysis. <i>BMC Medicine</i> , 2023, 21, .	2.3	2
987	Vaccinating women previously treated for human papillomavirus-related cervical precancerous lesions is highly cost-effective in China. <i>Frontiers in Immunology</i> , 0, 14, .	2.2	0
988	Parent-reported Barriers and Parental Beliefs Associated with Intentions to Obtain HPV Vaccination for Children in a Primary care Patient Population in Minnesota, USA. <i>Journal of Community Health</i> , 2023, 48, 678-686.	1.9	5
989	Autoimmune/inflammatory syndrome induced by adjuvants (ASIA) in 2023. <i>Autoimmunity Reviews</i> , 2023, 22, 103287.	2.5	24
990	Basic research on curcumin in cervical cancer: Progress and perspectives. <i>Biomedicine and Pharmacotherapy</i> , 2023, 162, 114590.	2.5	3
991	Electrochemical DNA-nano biosensor for the detection of cervical cancer-causing HPV-16 using ultrasmall Fe <sub>3</sub> O <sub>4</sub> -Au core-shell nanoparticles. <i>Sensing and Bio-Sensing Research</i> , 2023, 40, 100562.	2.2	2
992	Precision and correlation of ED50 and endpoint titer method in measuring HPV vaccine immunogenicity. <i>Journal of Virological Methods</i> , 2023, 316, 114716.	1.0	0
993	The impact of human papilloma virus on human reproductive health and the effect on male infertility: An updated review. <i>Journal of Medical Virology</i> , 2023, 95, .	2.5	4
994	Identifying intervention strategies to improve HPV vaccine decision-making using behaviour change theory. <i>Vaccine</i> , 2023, 41, 1368-1377.	1.7	4
996	A questionnaire study on disparity of cervical cancer prevention programs in <sc>Asia&Oceania</sc>. <i>Journal of Obstetrics and Gynaecology Research</i> , 2023, 49, 1230-1243.	0.6	2
997	Cervical HPV infection in Guangzhou, China: an epidemiological study of 198,111 women from 2015 to 2021. <i>Emerging Microbes and Infections</i> , 2023, 12, .	3.0	8
998	HPV Infection and Vaccination: A Question and Answer Guide for School Nurses. <i>NASN School Nurse (Print)</i> , 2023, 38, 134-144.	0.4	0
999	HPV and Cervical Cancer: A Review of Epidemiology and Screening Uptake in the UK. <i>Pathogens</i> , 2023, 12, 298.	1.2	20

#	ARTICLE	IF	CITATIONS
1000	HPV Vaccination Adherence in Working-Age Men: A Systematic Review and Meta-Analysis. <i>Vaccines</i> , 2023, 11, 443.	2.1	4
1001	Impact of nucleic acid extraction procedures on human papillomavirus (HPV) detection and genotyping. <i>Journal of Medical Virology</i> , 2023, 95, .	2.5	1
1002	Pembrolizumab with chemotherapy, with or without bevacizumab for persistent, recurrent, or metastatic cervical cancer. <i>Expert Opinion on Biological Therapy</i> , 2023, 23, 227-233.	1.4	2
1004	HPV Vaccination. , 2023, , 209-219.		0
1005	Cervical Cancer Prevention, Diagnosis, and Management Within a Low-Resource Environment. , 2023, , 225-286.		0
1006	Safety and immunogenicity of an Escherichia coli-produced 9-valent human papillomavirus L1 virus-like particle vaccine (types 6/11/16/18/31/33/45/52/58) in healthy adults: an open-label, dose-escalation phase 1 clinical trial. <i>The Lancet Regional Health - Western Pacific</i> , 2023, 34, 100731.	1.3	0
1007	Human papillomavirus (HPV) vaccination: a call for action in Italy. <i>International Journal of Gynecological Cancer</i> , 2023, 33, 1132-1139.	1.2	6
1008	Differences in HPV-specific antibody Fc-effector functions following Gardasil® and Cervarix® vaccination. <i>Npj Vaccines</i> , 2023, 8, .	2.9	6
1009	Prevalence of human papillomavirus DNA and p16INK4a positivity in vulvar cancer and vulvar intraepithelial neoplasia: a systematic review and meta-analysis. <i>Lancet Oncology</i> , The, 2023, 24, 403-414.	5.1	13
1010	Development and Validation of Two Optimized Multiplexed Serologic Assays for the 9-Valent Human Papillomavirus Vaccine Types. <i>MSphere</i> , 2023, 8, .	1.3	2
1011	Updates on cervical cancer prevention. <i>International Journal of Gynecological Cancer</i> , 2023, 33, 394-402.	1.2	10
1012	How to prevent human papillomavirus-related oropharyngeal cancer?. <i>Current Opinion in Oncology</i> , 2023, 35, 145-150.	1.1	1
1013	Vaccines and the Prevention of Dermatologic Diseases. , 2023, , 1501-1520.		0
1014	Worth a Pound of Cure? Emerging Strategies and Challenges in Cancer Immunoprevention. <i>Cancer Prevention Research</i> , 2023, 16, 483-495.	0.7	1
1015	Safety and immunogenicity of a pichia pastoris-expressed bivalent human papillomavirus (types 16 and 18) Tj ETQq0 0 0 rgBT /Overlock 10 placebo-controlled phase 1 clinical trial. <i>Vaccine</i> , 2023, 41, 3141-3149.	1.7	2
1016	An Integrative Approach, by Using a Bi-Digital O-Ring Test (BDORT), Advanced Bioinformatics, and Clinical Testing for the Development of New Effective Treatment of Infections Caused by Human Papillomaviruses (HPV). <i>Acupuncture and Electro-Therapeutics Research</i> , 2023, , .	0.0	0
1017	Anal Cancer in Systemic Lupus Erythematosus Patients is a Neglected Condition. <i>Journal of Coloproctology</i> , 2023, 43, 052-055.	0.1	0
1035	Epidemiology and Prevention. I-1. Epidemiology and Risk Factors. , 2023, , 289-292.		0

#	ARTICLE	IF	CITATIONS
1037	HPV-Impfung. , 2023, , 219-231.		0
1039	Technologies for Making New Vaccines. , 2023, , 1350-1373.e9.		0
1040	Human Papillomavirus Vaccines. , 2023, , 484-513.e11.		0
1077	Implications of HPV infectivity in early diagnosis and treatment of advanced/recurrent malignancies. , 2024, 2, .		0
1090	Evidence and Implementation of HPV Vaccination. Comprehensive Gynecology and Obstetrics, 2024, , 75-82.	0.0	0